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Abstract
Treatment for breast or prostate cancer can have negative consequences on working
life. In addition to sick leave during treatment, women and men with breast or
prostate cancer are at increased risk of permanent absence from work, although
data on the underlying reasons for this are sparse. The overall aim of this thesis
was to study the impact of breast and prostate cancer and their specific treatments
on sick leave and work using population-based Swedish register data.
Studies I and II examined the influence of prostate cancer treatment on sick
leave and receipt of disability pension. Two different types of surgery (robot-
assisted and open retropubic radical prostatectomy) were studied in men with low-,
intermediate- or high-risk prostate cancer, as were the treatment strategies (surgery,
radiotherapy, or active surveillance) for men with low- or intermediate-risk prostate
cancer. The studies included working-aged men diagnosed with prostate cancer
from 2007 onward and matched prostate cancer-free men identified in the Prostate
Cancer Data Base Sweden (PCBaSe). In 2,571 men with low-, intermediate-
or high-risk prostate cancer (Study I), we found that robot-assisted surgery was
associated with an earlier return to work compared with open surgery. Surgery
type, however, had no influence on long-term rates of sick leave and disability
pension receipt. In 8,699 men with low- or intermediate-risk prostate cancer
(Study II), men on active surveillance spent less than half as many days on sick
leave due to prostate cancer compared with those treated with primary radical
prostatectomy or primary radiotherapy in the first 5 years after diagnosis. At year
5 after diagnosis, there were no major differences in the proportion of men on sick
leave, disability pension, and death between treatment strategies.
Studies III and IV were based on working-aged women diagnosed with breast
cancer from 1997 onward and matched breast cancer-free women identified in
the Breast Cancer Data Base Sweden (BCBaSe). In Study III, we quantified the
permanent loss of working time due to breast cancer diagnosis and treatment.
Permanent loss was defined as disability pension receipt of at least 75%, early old-
age retirement, or death. The study included 19,661 women with breast cancer and
81,303 breast cancer-free women. We estimated that women aged 50 at diagnosis
on average lost between 0 years (for in situ and subgroups of stage I breast cancer)
and 8 years (for stage IV breast cancer) of their remaining working time due to
breast cancer. Study IV examined the underlying causes of sick leave and disability
pension receipt after a breast cancer diagnosis. In 16,603 women with stage I to
stage III breast cancer, we found that cancer was the most commonly reported
cause of sick leave and disability pension receipt, with cancer progression as the
strongest determinant. In addition, sick leave and/or disability pension receipt
due to lymphedema, fatigue-related conditions, mental disorders, cardiovascular
diseases, and inflammatory diseases was more common in women with breast
cancer compared with breast cancer-free women.
The results of this thesis show that prostate cancer treatment type has an impact
on sick leave and work mainly in the first year of diagnosis. Breast cancer may
have a considerable impact on working life, although it is reassuring that many
women with early-stage breast cancer are able to remain in the labor market.
Disease progression is not the only reason for absence from work in women with
breast cancer; our findings suggest that a wide range of physical and
physiological conditions underlie the increased risk of permanent absence from
work observed in both our studies and others. As a whole, the findings of this
thesis can be used to improve the management and rehabilitation of breast and
prostate cancer diagnosed in working-aged women and men.
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Svensk sammanfattning
Varje år drabbas över 7 000 svenska kvinnor och män i arbetsför ålder av bröst-
eller prostatacancer. Utredning och behandling av cancer kan ha både psykologiska
och fysiska konsekvenser, som i sin tur påverkar möjligheten att arbeta. För
många individer är arbete en viktig del av livet, som utöver ekonomisk trygghet
erbjuder ett socialt sammanhang och en känsla av att bidra till samhället. Efter
en cancerdiagnos kan möjligheten att arbeta vara särskilt viktig, då återgången till
arbetet kan betraktas som en normalisering av livet och ett tecken på återvunnen
hälsa.
Trots detta har bara ett fåtal studier undersökt långtidskonsekvenserna av bröst-
och prostatacancer på arbetslivet. De studier som finns pekar på att individer som
drabbats av cancer har en högre risk att vara sjukskrivna och få sjukersättning,
även så långt som fem år efter diagnos. Det är till viss del oklart varför kvinnor
och män med bröst- eller prostatacancer försvinner ut ur arbetslivet tidigare.
Denna avhandling syftade till att studera hur diagnos och behandling av bröst-
eller prostatacancer påverkar sjukskrivning och arbete baserat på data från
kvalitetsregister för cancer som länkats mot information från bland annat
Försäkringskassan.
I avhandlingens första två delarbeten studerade vi hur behandlingsstrategin för
prostatacancer påverkar sjukskrivning och sjukersättning upp till fem år efter
diagnos. Vi observerade att typ av behandling till stor grad påverkade
sjukskrivning under det första året efter diagnos. I en jämförelse av typ av kirurgi
för prostatacancer fann vi att män som opererats med robot-assisterad kirurgi
hade en kortare sjukskrivningsperiod än män som opererats med öppen kirurgi.
På lång sikt fanns dock inga skillnader i sjukskrivning och sjukersättning mellan
de två operationsteknikerna. I delarbete två jämfördes aktiv monitorering, kirurgi
och bestrålning bland män med låg- och intermediärrisk prostatacancer. Vi fann
att aktiv monitorering hade lägst påverkan på arbetslivet: Män som hade aktiv
monitorering som primär behandlingsstrategi hade mindre än hälften så många
dagar med sjukskrivning på grund av prostatacancer de första fem åren efter
diagnos än män som opererats eller bestrålats. Fem år efter diagnos var dock över
90% av männen, oavsett behandlingsstrategi, i arbete eller stod till
arbetsmarknadens förfogande.
I avhandlingens tredje och fjärde delarbete beräknade vi hur många arbetsår
som förloras på grund av en bröstcancerdiagnosis samt studerade de
underliggande medicinska orsakerna till sjukskrivning och sjukersättning hos
kvinnor med bröstcancer. I jämförelse med bröstcancerfria kvinnor fann vi att
50-åriga kvinnor i snitt förlorade upp till 8 år av förväntad kvarvarande arbetstid
som en konsekvens av sin bröstcancersjukdom. Kvinnor med in situ bröstcancer
och vissa kvinnor med gynnsamma prognostiska faktorer förlorade inga arbetsår.
Bland de underliggande orsakerna till sjukskrivning och sjukersättning hos
kvinnor med bröstcancer återfanns förutom cancer även flera andra
sjukdomstillstånd. Jämfört med bröstcancerfria kvinnor var det en större andel
kvinnor med bröstcancer som inte kunde arbeta på grund av lymfödem, trötthet
och smärtrelaterade besvär, depression, stress och ångest, samt kardiovaskulära
och inflammatoriska sjukdomar.
Sammantaget visar resultaten i denna avhandling på att behandling för bröst-
och prostatacancer kan ha en stor påverkan på arbetslivet. Resultaten kan användas
för att förbättra vården och utveckla program och arbetsplatsinsatser för kvinnor
och män som drabbats av cancer i arbetsför ålder.
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1 Introduction
Cancer is often considered a disease of the elderly. However, around one-third of
all cancers in Sweden are diagnosed in individuals under the age of 65. Many of
these individuals are in the midst of their working lives, which are often put on hold
because of the cancer diagnosis. As well as the treatment itself, treatment-related
adverse events may affect the ability to continue working. In addition to its impact
on lifetime earnings, not being able to work can also influence psychological
wellbeing. Work is an important aspect of life, offering a sense of belonging and
providing structure for daily life.
Breast and prostate cancer are the most common cancer diagnoses in
working-aged women and men. Women with breast cancer usually follow an
intense treatment protocol, with post-diagnostic sick-leave periods of up to a year.
Prostate cancer may also require more intensive treatment, but curative treatment
can often be postponed until signs of progression appear. Few previous studies
have researched the long-term influence of specific treatments for breast and
prostate cancer on sick leave and work. Such information is relevant in order to
improve quality of life for working-aged women and men diagnosed with cancer.
In the present thesis, we aimed to study the impact of diagnosis and treatment
of breast or prostate cancer on sick leave and work. In this work we also focused
on applying statistical methods that quantify this impact in absolute terms so as to
increase our understanding of how cancer influences working life.
Throughout this thesis, the term “working-aged” refers to individuals under the
age of 65, the standard retirement age in Sweden. Breast and prostate cancer are
rarely diagnosed in individuals under the age of 30.
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2 Background
2.1 Breast and prostate cancer in working-aged women and men
In 2016, approximately 50% of all breast cancers and 30% of all prostate cancers
in Sweden were diagnosed in working-aged people [1]. Over 7,000 working-aged
women and men received a diagnosis of breast or prostate cancer, which accounted
for 30% to 40% of all cancers in this age group. For people under the age of 65,
the cumulative risk of being diagnosed with breast cancer is 6%, and with prostate
cancer 5%.
The incidence of breast and prostate cancer in working-aged women and men
has increased in Sweden since the 1970s (Figure 2.1) [2]. Factors believed to
explain the rise in breast cancer incidence include changes in lifestyle factors and
the introduction of organized mammography screening programs [3]. The rise
in prostate cancer incidence most likely reflects the widespread use of prostate-
specific antigen (PSA) testing. This increased focus on early diagnosis, along
with more effective treatment [4], has led to reductions in both breast and prostate
cancer mortality (Figure 2.1) [5]. Today, more than 30,000 working-aged women
and 13,000 working-aged men live with a diagnosis of breast or prostate cancer in
Sweden.
In comparison with outcomes for many other types of cancer, survival rates for
breast and prostate cancer are high. In women diagnosed with breast cancer at
the age of 50 to 59, the most recent estimates of 5 and 10-year relative survival
are 94% and 88%, respectively [5]. In men diagnosed with prostate cancer, the
corresponding estimates are 96% and 92%.
The prognosis is strongly dependent on disease stage and other tumor
characteristics at diagnosis. For example, in an analysis of studies from the Early
Breast Cancer Trialist’s Collaborative Group on women with estrogen
receptor-positive breast cancer diagnosed before the age of 75, the 10-year
cumulative risk of breast cancer-specific death was 8% in women with no lymph
node involvement at diagnosis, compared with 29% in women with 4 to 9
involved lymph nodes [6]. Based on data from the National Prostate Cancer
Register of Sweden, the 10-year cumulative risk of prostate cancer-specific death
in men with localized disease aged 60 at diagnosis was 1% in men in the lowest
risk category, compared with 12% in the highest risk category [7].
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Figure 2.1: Age-standardized incidence and mortality (per 100,000) of breast and
prostate cancer in women and men aged less than 65 years at diagnosis
2.2 Prostate cancer: diagnosis, classification, and treatment
2.2.1 Diagnosis and classification
Symptoms of prostate cancer generally only occur during more advanced stages of
the disease, and include frequent urination, weak urine flow, and difficulty starting
or stopping urine flow. The number of men diagnosed with asymptomatic prostate
cancer has increased in Sweden since PSA testing became available. From 2004
to 2016, the proportion of tumors detected during health checkups increased from
29% to 53% [8]. This resulted in a steep decrease in the median age at diagnosis,
from 74 years in 1996 to 70 years in 2005 [9].
The diagnosis of prostate cancer is confirmed through biopsy. Prostate cancer
is classified histologically according to the Gleason grading system [10]. By
characterizing and assigning a grade to the most prevalent and the second-most
prevalent tumor growth patterns, a summary score is calculated and assigned using
the Gleason grade grouping system (GGG) (Table 2.1); the higher the assigned
GGG, the worse the prognosis.
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Table 2.1: Gleason Grade Group
Gleason Grade Group Gleason Score Gleason Pattern
1 ≤ 6 ≤ 3 + 3
2 7 3 + 4
3 7 4 + 3
4 8 4 + 4
5 9–10 4 + 5, 5 + 4, 5 + 5
Localized prostate cancer can be classified into 4 risk categories: very low-,
low-, intermediate- and high-risk disease (Table 2.2) [11]. Based on data from
the National Prostate Cancer Register [12], in 2017, 41% of men under the age
of 65 were diagnosed with low-risk disease, 37% with intermediate-risk disease,
11% with high-risk disease, 3% with regionally metastasized disease, and 5% with
metastatic disease.
Table 2.2: Risk categories for localized prostate cancer
Risk
category
Very low T1c (detection through needle biopsy), PSA density < 0.15 µg/l/cm3, ≤
8 mm total cancer length in ≤ 4 biopsy cores
Low T1 (not palpable) - T2a (involves one-half of 1 lobe or less), GGG 1,
PSA < 10 µg/l
Intermediate T2b (involves more than half of 1 lobe), GGG 2-3, and/or PSA 10 to <
20 µg/l
High T2c (involves both lobes) - T3 (extends through the prostatic capsule),
GGG 4-5 (or extensive 3), and/or PSA ≥ 20 µg/l
2.2.2 Treatment
Men with localized prostate cancer have several treatment options: radical
prostatectomy, radiotherapy, hormone therapy, active surveillance, and watchful
waiting. Treatment decisions are based upon tumor characteristics, life
expectancy, and individual preferences. Since 2007, Swedish guidelines have
recommended active surveillance as the first-choice treatment for men with
low-risk prostate cancer [11]. Active surveillance is a strategy that delays curative
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treatment until signs of disease progression appear, and includes blood tests every
3 to 6 months, rectal examinations every 6 to 12 months, and a biopsy every
second to third year.
In 2017, the percentage of men aged 64 or younger managed using active
surveillance was 93% in the very-low-risk group, 71% in the low-risk group, and
16% in the intermediate-risk group [12]. Watchful waiting is another strategy for
men with a life expectancy of less than 10 to 15 years for whom subsequent
curative treatment is not an option. Typically, these men receive hormone therapy
starting from the time of symptomatic progression.
Radical prostatectomy and radiotherapy are commonly used to treat
intermediate- and high-risk prostate cancer. Radical prostatectomy is a surgical
procedure to remove the whole prostate gland, with or without surrounding lymph
nodes. It can either be performed as an open procedure (retropubic radical
prostatectomy) or with traditional or robot-assisted laparoscopic techniques. The
advantages of robot-assisted radical prostatectomy over open surgery are
decreased bleeding and shorter hospital stays [13], but previous studies have
found no major differences in functional outcomes [14, 15].
External beam radiotherapy is another standard option for treatment of prostate
cancer, especially for larger tumors with possible growth outside the prostate
gland. This technique has the advantage of not requiring anesthesia and hospital
stays, but its disadvantage is a small risk of secondary cancers [16]. Radiotherapy
is usually given for up to 8 weeks and can be combined with hormone therapy.
Brachytherapy is a further option in which radioactive seeds are placed in the
prostate. In a randomized trial comparing radical prostatectomy, external beam
radiotherapy, and active surveillance for the treatment of localized prostate cancer
(the ProtecT trial), the 10-year prostate cancer-specific mortality rate was similar
across all treatment groups [17].
Recurrence is not uncommon after treatment for prostate cancer: A study based
on the National Prostate Cancer Register of Sweden found that around one-fifth
of men with localized prostate cancer treated with radical prostatectomy
experienced disease progression within the first 10 years [18]. For these men,
possible treatment options include salvage radiotherapy, hormone therapy, or
watchful waiting. Hormone therapy—also called androgen deprivation therapy
(ADT)—is the first-choice treatment for localized high-risk, recurrent, or
metastatic prostate cancer. Hormone therapy is aimed at lowering testosterone
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levels through either surgical (orchiectomy) or medical castration. The most
frequently used agents for medical castration are gonadotropin-releasing hormone
(GnRH) agonists and anti-androgens.
2.2.3 Treatment-related adverse events and quality of life
Due to the location of the prostate, the most common adverse events after radical
prostatectomy and radiotherapy involve erectile, urinary, and bowel functions. In
the ProtecT trial, 67% of men had an erection firm enough for intercourse at
baseline [19]. Six months later, this proportion had fallen to 12% in the
prostatectomy group, 22% in the radiotherapy group, and 52% in the active
surveillance group. Long-term data on erectile function are available from a
follow-up study performed within the National Prostate Cancer Register of
Sweden (NPCR follow-up study) [20]. After a median follow-up of 12 years after
diagnosis, normal erectile function was reported in 11% of men treated with
prostatectomy, 16% of men treated with radiotherapy, and 20% of men with
active surveillance as the primary management strategy, compared with 35% of
age-matched prostate cancer-free men.
Men treated with radical prostatectomy are at a particularly high risk of urinary
incontinence. In the ProtecT trial, 46% of men in the prostatectomy group used
absorbent pads at 6 months, compared with 5% in the radiotherapy group, and
4% in the surveillance group [19]. In the NPCR follow-up study, 21% of men
treated with prostatectomy, 9% of men treated with radiotherapy, and 8% of men
on active surveillance used pads [20]. Bowel dysfunction is primarily a concern
after radiotherapy. In the ProtecT trial, the proportion of men in the radiotherapy
group reporting blood in stools increased from 1.6% at baseline to 3.8% at 6
months [19]. In the NPCR follow-up study, men treated with radiotherapy had
a 2-fold increased risk of bowel dysfunction compared with prostate cancer-free
men [20].
Men under multimodal treatment, especially combinations that include
hormone therapy, generally have the highest risk of adverse events [20, 21].
Hormone therapy is associated with an increased risk of a range of adverse events
including erectile dysfunction, enlarged breasts, hot flashes, cognitive impairment,
depression, osteoporosis, and cardiovascular and other metabolic diseases [22].
For example, a recent meta-analysis of 18 studies found that use of hormone
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therapy in men with prostate cancer was associated with a 1.4-fold increased risk
of depression [23].
Prostate cancer has been reported to have an impact on general well-being. In
the Scandinavian Prostate Cancer Group Study Number 4 trial (SPCG-4), in which
radical prostatectomy was compared to watchful waiting with additional data on
a population-based control group, 35% of men in the prostatectomy group, 34%
of men in the watchful waiting group and 45% of control men reported a high
quality of life after a median follow-up of 12 years [24]. A recent Dutch study
also reported poorer quality of life in men with prostate cancer compared with
population-based control men [25].
Problems related to mental health are of particular concern after a prostate cancer
diagnosis. In the Dutch study, 14% of men with prostate cancer had clinically
relevant mental health problems 5 years or more after diagnosis, compared with
6% in control men [25], which is largely consistent with results from an earlier
meta-analysis [26]. More urinary issues and decreased sexual satisfaction were
significant predictors of poorer mental health [25]. In a Swedish study based
on data from the National Prostate Cancer Register of Sweden, men in all risk
categories were at increased risk of use of antidepressant medication [27].
2.3 Breast cancer: diagnosis, classification, and treatment
2.3.1 Diagnosis and classification
Approximately 65% of all breast cancer in Sweden is detected by mammography
screening, which is offered to women aged 40 to 74 years within an invitational
screening program [28]. The remaining tumors are detected by clinical signs and
symptoms reported by the woman herself, the most common of these being a lump.
The median age at diagnosis in Sweden in 2017 was 65 years, with an interquartile
range of 54 to 73 years.
Diagnosis of breast cancer is based on clinical examination, imaging, and
biopsy. Breast cancer is broadly categorized into in situ and invasive cancer, of
which ductal and lobular are the most common subtypes. Invasive breast cancer is
further classified by expression of estrogen receptor (ER), progesterone receptor
(PR), human epidermal growth factor receptor 2 (HER2), and the cellular
proliferation marker Ki-67. Four molecular subtypes of breast cancer have been
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defined accordingly, each with distinct clinical and prognostic features (Table 2.3)
[29].
Table 2.3: Molecular subtypes of breast cancer
Subtype
Luminal A ER and/or PR positive, HER2 negative, low Ki-67
Luminal B ER and/or PR positive, HER2 negative, high Ki-67
HER2-positive HER2 positive
Triple-negative/basal-like ER and PR negative, HER2 negative
The most commonly used staging system for breast cancer is the American
Joint Committee on Cancer TNM system (Table 2.4) [10]. In 2017, the majority
of Swedish women diagnosed at under the age of 65 had luminal A or B breast
cancer (71%), no lymph node involvement (85%), and no distant metastasis at
diagnosis (98%) [28].
Table 2.4: TNM classification of breast cancer
Stage T-stage N-stage M-stage
0 In situ N0 M0
IA T1 (≤ 20 mm) N0 M0
IB T0–T1 (≤ 20 mm) N1 (micrometastases) M0
IIA T0–T1 (≤ 20 mm) N1 (1–3 axillary lymph nodes) M0
T2 (> 20 to ≤ 50 mm) N0 M0
IIB T2 (> 20 to ≤ 50 mm) N1 (1–3 axillary lymph nodes) M0
T3 (> 50 mm) N0 M0
IIIA T0–T2 (≤ 50 mm) N2 (4–9 axillary lymph nodes) M0
T3 (> 50 mm) N1-N2 (1–9 axillary lymph nodes) M0
IIIB T4 N0-N2 (≤ 9 axillary lymph nodes) M0
IIIC Any T N3 (≥ 10 axillary lymph nodes) M0
IV Any T Any N M1
2.3.2 Treatment
Surgery removing parts of the breast (partial mastectomy/breast-conserving
surgery) or the whole breast (mastectomy) is often the first line of treatment in
women with breast cancer [29]. Mastectomy is indicated when breast-conserving
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surgery is not possible due to tumor size or multifocal tumor growth, or because
of aesthetic concerns or patient preferences. Breast-conserving surgery with
post-operative radiotherapy is not associated with a survival disadvantage
compared with mastectomy [30, 31].
Staging of the axillary lymph nodes is usually performed at the same time as
breast cancer surgery. Axillary lymph node dissection, removing some or all of
the lymph nodes, was the standard procedure until the early 2000s. Today, the
primary method for axillary staging is sentinel lymph node biopsy, in which only
the first lymph node that drains the tumor is examined. In case of a positive
sentinel node biopsy, axillary lymph node dissection of at least 10 lymph nodes is
recommended. Randomized trials comparing sentinel node biopsy to axillary
lymph node dissection have found similar overall survival rates for the two
strategies, but with a considerably lower risk of adverse effects such as
lymphedema after sentinel node biopsy [32].
Post-operative radiotherapy is standard treatment following breast-conserving
surgery, and may be administered after mastectomy in cases with large tumors or
lymph node involvement. Radiotherapy is usually given 5 days per week during
5 weeks, sometimes followed by a supplemental boost of radiation. Adjuvant
chemotherapy can further reduce the risk of recurrence, and is recommended
for women with ER-negative tumors, women with lymph node involvement, or
women without lymph node involvement but with a high risk of recurrence [29].
Chemotherapy is typically given every third week for 6 cycles, and the most
common types chemotherapy used are anthracyclines and taxans, either alone
or in combination, or a combination of cyclophosphamide, methotrexate, and
fluorouracil. Around 50% of Swedish women aged 65 years or under at diagnosis
received chemotherapy in 2017 [28].
Women with HER2-positive tumors—about 15% of all breast cancers—benefit
from chemotherapy combined with HER2-targeted therapy (Trastuzumab). For
women with ER-positive tumors, additional endocrine treatment is recommended.
The selective estrogen receptor modulator Tamoxifen is indicated in
pre-menopausal women, whereas aromatase inhibitors are recommended for
post-menopausal women. Radiotherapy and chemotherapy are usually completed
within 4 to 6 months after surgery, while HER2-targeted therapy is given for 1
year and endocrine treatment is recommended for 5, or sometimes 10 years.
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2.3.3 Treatment-related adverse events and quality of life
Adverse events such as pain, fatigue, and lymphedema are common after
treatment for breast cancer. In a meta-analysis of 23 studies, nearly 40% of
women were reported to suffer from persistent pain after breast cancer surgery,
with axillary lymph node dissection as the strongest risk factor [33]. A
meta-analysis of 27 studies reported that approximately 25% of women treated
for breast cancer develop severe fatigue [34] that may persist for 10 years after
diagnosis [35]. Chemotherapy is one of the most important risk factors for
fatigue: 80% to 96% of women undergoing chemotherapy experience fatigue
during the treatment phase [36]. However, the association between chemotherapy
and persistent long-term fatigue is weaker [37]. Lymphedema is another adverse
event affecting around 20% of all women treated with axillary lymph node
dissection [38].
Several other conditions have been associated with treatment for breast cancer,
such as cardiovascular disease (which has been linked to anthracyclines,
trastuzumab, and radiotherapy); osteoporosis (linked to aromatase inhibitors);
infertility and menopausal symptoms (linked to chemotherapy and tamoxifen);
joint symptoms (linked to aromatase inhibitors); and secondary cancers (linked to
chemotherapy, radiotherapy, and tamoxifen) [39, 40]. Breast cancer has also been
associated with an increased risk of depression, anxiety, and stress-related
disorders, especially during the first years after diagnosis [41, 42]. The highest
risk of depression has been observed in young women, women with nodal
involvement, and women with comorbidities [42].
In a Danish study of long-term breast cancer survivors, around 20% reported that
their daily activities were limited by treatment sequelae [43]. The proportion was
highest in working-aged women, among whom up to 30% reported limited daily
activities. Although breast cancer is associated with a high morbidity burden, the
overall quality of life in women with breast cancer has been found to be similar to,
or sometimes better than, that reported by women of the same age in the general
population with the exception of the initial period after diagnosis [44–46] and
women diagnosed with breast cancer before the age of 50 [45, 47].
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2.4 Work after cancer
2.4.1 Presumptions and definitions
For many women and men, work is a central part of life that can provide a sense
of belonging, a structure for the day, and a feeling of contributing [48]. Previous
research has found that cancer patients often have a desire and need to re-engage in
paid work, not only to meet financial needs, but also to regain a sense of normality
[49, 50]. Returning to work can be a sign of recovery, marking the transition
from disease to regained health. Being able to work is also an important factor
associated with good quality of life after treatment for cancer [51, 52].
Diagnosis and treatment for cancer can affect working life in many different
ways, and a broad range of work-related outcomes has been investigated in
previous studies. In the cancer and work model initially proposed by Feuerstein et
al., 4 major types of outcomes were recognized (Table 2.5) [53].
Table 2.5: Different types of work-related outcomes
Outcomes Definition
Return to work Return to full-time work after diagnosis or treatment
Work ability Refers to “an individual’s psychological, physical, and
social means to engage in work” [53, p. 432]
Work performance Includes, for example, absenteeism from work due to sick
leave, work productivity, and perceived impairments while
at work
Sustainability Remaining employed or remaining in the work force
Feuerstein et al. also identified factors influencing these outcomes, and
categorized them into factors related to health (e.g., comorbidities), symptoms of
treatment (e.g., fatigue), functional abilities (e.g., strength), work demands (e.g.,
number of clients), work environment (e.g., flexibility), and legal and economic
factors (e.g., possibility of obtaining disability benefits).
Another commonly used term is work disability, defined “as occurring when a
worker is unable to stay at work or return to work because of an injury or disease”
[54, p. ix]. Temporary work disability is generally labeled sickness absence or sick
leave, whereas permanent work disability refers to a permanent reduction (part or
full-time) in work time, often accompanied by the receipt of a disability pension.
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Inherently, the inability to work is related to the demands at work. Therefore,
work disability is not necessarily a measure of morbidity, and can be regarded as
an “integrated measure of functioning” [55, p. 129].
2.4.2 Swedish legislation
As a part of the Swedish welfare system, all residents with a minimum income from
work or unemployment benefits are eligible for sickness benefits in the event of
work incapacity of at least 25% due to disease or injury [56]. The first 14 days of a
sick-leave period are paid by the employer, with the first day being a qualifying day
with no benefits paid. For sick-leave periods longer than 14 days, sickness benefits
are paid by the Swedish Social Insurance Agency, with benefits corresponding to
about 80% of an individual’s income up to a certain ceiling. Special rules apply
for the unemployed and self-employed, for whom the Swedish Social Insurance
Agency also compensates the first days that are paid by the employer in other
situations. In addition, those who are self-employed can choose to have longer
qualifying periods (up to 90 days). In case of permanent work incapacity, the
Swedish Social Insurance Agency can grant disability pensions to persons aged
30 to 64 years living in Sweden. A person can receive part or full-time sickness
benefit.
The Swedish Social Insurance system has undergone several changes [57].
During certain periods, the initial period of sick leave paid by the employer was
longer (28 days between January 1997 and March 1998, and 21 days between
July 2003 and December 2004). In 2003, the insurance for disability pensions
was transferred from the public pension system to the public sickness insurance
system. The method for calculating disability benefits changed, but the eligibility
criterion—reduced work capacity due to a health problem—remained the same.
In 2008, the rules for sick leave and disability pension receipt became stricter. A
time limit for sick leave was introduced, restricting the ability to obtaining sick
leave for more than a year. A stricter assessment of work ability was also
imposed, with fixed time-points for assessment at 90 and 180 days after the start
of the sick-leave period. To obtain a disability pension, work capacity has to be
permanently reduced for the foreseeable future, and the assessment must be made
against the labor market as a whole.
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2.4.3 Swedish guidelines on sick leave
Several stakeholders are involved in the sick-leave process. The physician is
responsible for diagnosis and treatment decisions, assessing work capacity, and
for determining the duration of the sick leave, all the while respecting individual
needs. The Social Insurance Agency makes the final decision based on the
information provided by the physician. The guidelines in Table 2.6 were
introduced by the National Board of Health and Welfare in 2007 to help both
physicians and insurance officers with the process, although every decision must
be based on individual circumstances [58].
Table 2.6: Cancer-specific guidelines for sick leave
Type of cancer/treatment Recommended sick leave
Breast cancer
Partial mastectomy with minor
axillary surgery
Up to 3 weeks
Mastectomy and/or extensive
axillary surgery
Up to 6 weeks
Adjuvant chemotherapy Often requires full-time sick leave
Radiotherapy Sick leave can be indicated because of practical
reasons or adverse events from previous
treatments
Endocrine or HER2-targeted therapy Usually allows for at least part-time work
Prostate cancer
Radical prostatectomy Up to 6 weeks
Radiotherapy Can require up to 8 weeks sick leave during the
latter part of the treatment due to adverse
events
Metastatic breast or prostate
cancer
Extended sick leave can be required, often 1
year or longer
2.4.4 Previous research on work after prostate cancer
Return to work
Time to return to work after surgery for prostate cancer has been examined in a few
previous studies [59–65]. Two studies from the United States reported a median
absence of 25 days or less after radical prostatectomy [59, 61], whereas European
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studies generally report longer absences from work. Two German studies found
a median time to return to work after radical prostatectomy of 42 and 56 days,
respectively [62, 63]. In a Swedish/Danish study, a median of 55 days of sick
leave was reported for men treated with open radical prostatectomy, compared
with 26 days for men treated with robot-assisted radical prostatectomy [60].
Return to work after other types of treatment for prostate cancer has been less
thoroughly studied. In one of the US-based studies, hormone treatment and/or
radiotherapy was associated with a median of only 3 days of absence from work
in the first 6 months after diagnosis [59]. A Danish study examined the duration
of sick leave after radiotherapy and hormone therapy and found a median duration
of 9 weeks in the first year after the start of treatment [66].
Over 80% of men with prostate cancer are able to return to work within the first
year of diagnosis [63, 67]. In addition to treatment type, factors associated with a
delayed return to work in men with prostate cancer are high tumor stage [60, 63],
high physical workload or manual work [60–62, 65], young age [61, 63, 65], and
low income or education [60, 62, 65].
Work-related aspects beyond return to work
Treatment for prostate cancer can also have a long-term impact on working life,
although only a limited number of studies on this aspect have been published. A
Norwegian study examined sick leave after prostate and other cancers and found
that men with prostate cancer had a 1.6-fold increased risk of sick leave 5 years
after diagnosis compared with a control population (Figure 2.2) [68]. In two
Danish studies with up to 20 years of follow-up, it was reported that men with
prostate cancer had a 4-fold increased risk of early retirement pension before the
age of 60 [69], but no increased risk of unemployment [70]. A Finnish study also
found that prostate cancer was associated with a small increased risk of
retirement, but not with unemployment [71]. In the Nordic Study on Cancer and
Work (NOCWO), men with prostate cancer had an increased risk of
non-employment, which included unemployment, disability pension receipt, and
retirement [72].
Self-reported work ability has been examined in men with prostate cancer. In
the NOCWO study, men with prostate cancer reported a lower ability to work than
control men [73]. Another study found that while most men are able to continue
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Figure 2.2: Odds ratio of sick leave five years after diagnosis
to work after radical prostatectomy, the cancer diagnosis has a negative impact
on working life 3 years after the surgery in 34% of the men still working [74].
In an extended analysis partly based on the same cohort of men, 24% reported a
moderate or poor ability to work during a period of up to 6 years after surgery
[75]. Men who underwent surgery less than 3 years ago and men with additional
hormone therapy and/or radiotherapy were at the highest risk for moderate or poor
ability to work.
In a recently published study from the United Kingdom, the treatment type for
prostate cancer influenced the transition from employment to unemployment 18 to
42 months after diagnosis [76]. A larger proportion of men receiving radiotherapy
and/or hormone therapy moved to unemployment compared with men treated with
surgery only or men on active surveillance or watchful waiting.
Underlying medical reasons for absence from work
Treatment-related symptoms can negatively influence employment and work. In
a Norwegian study of men who had undergone radical prostatectomy, a reduction
in physical functioning was associated with reduced work status 3 months after
surgery [65]. In two other studies from the same research group, fatigue and
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urinary leakage were factors that were strongly related to perceived work ability
up to 6 years after surgery [74, 75]. In the study from the United Kingdom,
moderate or severe urinary and bowel symptoms were associated with a 2-fold
increased risk of becoming unemployed [76].
2.4.5 Previous research on work after breast cancer
Return to work
The majority of women diagnosed with breast cancer are able to return to work
within 1 year after diagnosis. In one Swedish study, 83% of women with early-
stage breast cancer had returned to work 10 months after diagnosis [77]. The
proportion was lower in women treated with chemotherapy (63%), and higher in
women not treated with chemotherapy (91%). Four other Swedish studies [50,
78–80] and several studies from other European countries [81–83] have reported
similar estimates of return-to-work, ranging from 68% to 79% at 11 to 12 months
after diagnosis.
Time to return to work—usually measured as the duration of sick leave—after a
breast cancer diagnosis has been examined in a few previous studies [59, 84, 85].
In a French study, the median duration of sick leave was 11 months [85].
Chemotherapy was associated with longer sick leave (15 months), as was
mastectomy (13 months), axillary lymph node dissection (13 months), and
radiotherapy (12 months). Similar durations of absence from work were observed
in a study from the Netherlands [84], whereas considerably shorter absences (less
than 2 months) were reported in a study from the United States [59]. Other
studies have examined the number of days on sick leave in the first year after
diagnosis [86–90]. For example, in a nationwide Swedish study, Kvillemo et al.
observed that women diagnosed with all stages of breast cancer had a mean of
185 days of sick leave or disability pension receipt in the first year after diagnosis,
compared with less than 80 days in matched control women [86].
In a systematic review including 26 studies, chemotherapy was reported to be
one of the major factors negatively influencing time to return to work after a
breast cancer diagnosis [91]. Other treatment-related factors frequently reported
to delay return to work were mastectomy and axillary lymph node dissection.
Among the work-related factors, workplace support from employers and
colleagues was reported to be the key factor for facilitating return to work.
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Figure 2.3: Percentage of women on sick leave and disability pension by year since
diagnosis
Several sociodemographic factors were also reported to facilitate return to work,
including high income, high educational level, and social support from family and
friends.
Work-related aspects beyond return to work
Breast cancer can also have negative consequences on work and employment
beyond the first year after diagnosis. Three Swedish register-based studies have
examined the risk of sick leave and disability pension receipt in women with breast
cancer during the first 5 years after diagnosis in comparison with matched breast
cancer-free control women [86, 89, 92]. Eaker et al. observed that breast cancer
was associated with a 1.2-fold increased risk of sick leave and a 1.5-fold increased
risk of disability pension receipt 5 years after diagnosis [92]. An increased risk
was found across all disease stages. The two other Swedish studies also found
evidence of an increased risk of sick leave in women with breast cancer 3 years
[89] and 5 years after diagnosis [86]. In the study by Kvillemo et al., 19% of
women with breast cancer and 11% of control women had at least 1 period of
sick leave in the fifth year after diagnosis, after excluding those no longer at risk
(Figure 2.3) [86]. Receipt of disability pension benefits was reported in 23% of
women with breast cancer and 20% of control women.
The long-term risk of sick leave and disability pension receipt has also been
examined in studies from other European countries. Two Norwegian studies
reported a 1.5-fold increased risk of sick leave in year 5 after diagnosis (Figure
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2.2) [68] and a 2.7-fold increased risk of disability pension receipt during a period
of up to 14 years after diagnosis [93]. In a Danish study it was observed that
women with breast cancer was the only group of cancer survivors that still had a
significantly increased risk of early retirement pension before the age of 60 after
12 years of follow-up [69]. In a Dutch study by Paalman et al., the 10-year
cumulative incidence of disability pension receipt was 33% in women with breast
cancer, compared with 14% in control women [94].
Other studies have assessed rates of unemployment or non-employment, which
is a mixture of different types of absences, in the years following a breast cancer
diagnosis. In a recently published cohort study of women with early-stage breast
cancer in the Unites States, 56% of women with breast cancer and 63% of control
women were still employed 2 years after diagnosis [95]. Another research group
from the United States reported that women who remained free from recurrence
did not, on average, spend much more time away from work in the third year after
diagnosis (2.1 months) compared with control women (1.9 months) [90]. However,
the duration of absence was considerably higher in women with new cancer events
(4.1 months). In the study by Paalman et al., women with breast cancer were at
increased risk of unemployment [94], whereas no increased risk was found in an
older Finish study [71].
Self-reported work ability has also been examined in a few studies. Danish
women living with breast cancer for at least 5 years reported lower work ability
than control women [96], and similar findings were reported in two other studies
[73, 97]. In a recent study from Singapore, approximately 40% of employed
women with breast cancer had poor or moderate work ability 1 year or more after
diagnosis [98]. While a Norwegian study reported poorer work capacity in women
with breast cancer who had returned to work compared with control women, breast
cancer had no impact on working hours or the proportion of full-time workers [99].
In addition to the adverse influence of a more advanced disease stage at
diagnosis, most previous studies with data on tumor and treatment characteristics
have reported an impact of treatment type on long-term absence from work: For
example, in the study by Eaker et al., mastectomy, axillary lymph node dissection,
chemotherapy, and hormonal therapy were independently associated with an
increased risk of sick leave and disability pension receipt 3 years after diagnosis,
with somewhat weaker associations in year 5 [92]. Paalman et al. also observed
an increased risk of disability pension receipt after axillary lymph node dissection
19
up to 10 years after diagnosis, but not after mastectomy alone or hormonal
therapy [94]. Chemotherapy was associated with an increased risk only in the first
5 years after diagnosis. In a cohort of women from the United States with
early-stage breast cancer, chemotherapy, but not mastectomy, was also associated
with an increased risk of unemployment 4 years after diagnosis [100]. In contrast
to these studies, two Danish studies found no evidence that chemotherapy
increased the risk of unemployment 2 years after diagnosis [101] or early
retirement during a mean follow-up of 3 years [102].
Underlying medical reasons for absence from work
During the first year following diagnosis, women with breast cancer are absent
from work in order to undergo treatment; treatment modality is a major
determinant of time to return to work. Treatment-related adverse events such as
pain in the breast, arm and shoulder function impairments, and lymphedema have
been noted to delay return to work [84, 85, 103]. In a small Swedish study of 14
women who remained on sick leave 8 months after diagnosis, reasons for sick
leave on the medical certificate were related to systemic adverse events [79].
The medical reasons for sick leave and other types of absence from work beyond
the first year have rarely been studied. Kvillemo et al. included medical diagnoses
for sick leave in their analysis, and observed that breast cancer was the reported
cause in 42% of days on sick leave and 12% of days on disability pension in
year 5 after diagnosis [86]. The corresponding numbers for the remaining causes
were not presented. A few other studies have examined whether certain symptoms
are related to absence from work following diagnosis. Fatigue and pain have
been associated with an increased risk of not being employed [95, 104]. Sleep
disturbances have also been identified as a mediating factor for absence from work,
accounting for 8% of missed work days in women and men with breast or prostate
cancer [105].
A number of studies have examined factors affecting work ability in the years
following a breast cancer diagnosis. Fatigue has been identified as a major factor
explaining work ability and work limitations in women with breast cancer [106,
107]. In the Danish study of self-reported work ability in women with breast
cancer, fatigue was associated with an 11-fold increased risk of impaired work
ability [96]. After fatigue, the strongest associations were observed for anxiety,
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low income, and little support from supervisors, which were associated with a
2-fold increased risk of impaired work ability.
Breast and arm symptoms have also been reported to reduce work ability and
work capacity in women with breast cancer [98, 108]. In a study of Canadian
women with breast cancer, those with arm pain had an 8-fold increased risk of
reduced work capacity compared with those with no arm pain [108]. In a recent
systematic review including both quantitative and qualitative studies, physical
impairments were consistently described as negatively influencing work ability
and return to work, whereas findings regarding cognitive functioning conflicted
[109].
2.4.6 Methods used in previous studies on work and cancer
Study designs
Most previous quantitative studies on work and cancer have had a cross-sectional
or prospective cohort design [91, 110–112]. In a systematic review of employment
after different types of cancer, 23 out of 64 studies (36%) included a comparison
group [111]. In another review, it was observed that only 7 out of 28 cohort studies
(25%) were population-based [112]. Several authors have pointed out that there is
a lack of high-quality prospective studies investigating the medium and long-term
impact of cancer on employment and work [110–112].
Ways of measuring absence from work
In addition to the many different types of work-related outcomes that have been
studied, there are also differences between studies in how outcomes have been
measured. Already in the 1960s, a study identified 41 different ways of measuring
absence from work [113]. The topic has been discussed in later reviews, and
reflects that multiple scientific disciplines are involved [114, 115]. Furthermore,
to understand and delineate the complete picture of absence from work, several
measures may be needed.
In 1998, Hensing et al. suggested some basic measures to be used in studies
examining sick leave related to (1) number of sick-leave spells or episodes, (2)
number of days on sick leave, or (3) number of individuals who are sick-listed
[114]. The choice of denominator is crucial: the researcher must decide if
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denominator should include all sick leave-insured individuals (i.e., all individuals
at risk) or individuals on sick leave only. A further issue is that the degree of sick
leave can vary; should part-time sick leave be handled the same way as full-time
sick leave? Some previous studies have examined the net number of days on sick
leave by multiplying the number of days on sick leave by the degree of
compensation [86, 88, 89].
Another issue is self-reported sick leave versus register-based sick leave. Most
of the Swedish studies reporting on sick leave after breast and prostate cancer have
used register-based data, which are considered more reliable than self-reported
data [115].
Commonly used statistical methods and their limitations
In most previous studies examining sick leave and disability pension receipt, the
data have been analyzed either with a count model such as Poisson regression or
standard survival analysis using Cox proportional hazards regression [116]. In a
Poisson model, the outcome variable is a count or a rate of, for example, the total
number of days on sick leave and disability pension during a defined follow-up
period. The underlying assumption of a Poisson model that the variance should
be equal to the mean is often violated in sick-leave data. In many settings, most
individuals have zero days of sick leave whereas those with sick leave are absent
for long periods. This means that the data is heavily skewed, and the variance is
larger than the mean. If the variance is larger than expected under the Poisson
distribution, the data are considered to be overdispersed. Ignoring overdispersion
leads to too-small standard errors and too-narrow confidence intervals. Some
previous studies have used (zero-inflated) negative binomial regression [117] or
linear regression with non-parametric bootstrap to obtain confidence intervals
[118]. Authors of other studies have categorized sick leave into a binary variable
and performed a logistic regression [86, 92].
In a Cox model, the time until the occurrence of an event is of interest. In
a standard Cox regression, only the first occurrence of an event is considered,
which is usually appropriate for studies of disability pension receipt or return to
work. However, this is a potential problem in studies on sick leave, since sick
leave can occur repeatedly. Although seldom used, survival analysis for recurrent
events is generally more suitable for sick-leave data [119]. Furthermore, many
previous studies have failed to consider competing events. Competing events are
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Figure 2.4: Percentage of women on sick leave by year since diagnosis
present if an individual is at risk of more than one mutually exclusive event, and
the occurrence of one event will prevent the other event from happening.
In studies of sick leave in cancer patients, two obvious competing risks are
receipt of disability pension and death. An illustrative example of this is presented
in the study by Eaker et al., in which the proportion of women on sick leave in
years 3 and 5 after diagnosis was presented stratified by disease stage [92]. In
year 3, the proportion of women taking sick leave was 38% in women with stage
III–IV disease, and 25% in women with stage I disease (Figure 2.4). In year 5,
the relationship was reversed: only 22% of women with stage III–IV and 24% of
women with stage I disease took sick leave. Instead, over 30% of women with
advanced stage disease who were still alive had moved on to disability pension,
whereas 36% of women who were initially part of the study population had died.
Not considering or presenting estimates of competing events can therefore lead to
erroneous conclusions regarding absence from work.
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3 Aims
The overarching aim of this thesis was to study the impact of the diagnosis and
treatment of breast and prostate cancer on sick leave and work.
The specific research questions were:
Study I: Do men with prostate cancer treated with robot-assisted radical
prostatectomy return to work earlier and experience lower rates of long-term work
disability than men treated with retropubic radical prostatectomy?
Study II: How much time is lost from work due to sick leave and disability pension
receipt in men with prostate cancer on active surveillance as compared with men
undergoing primary radical prostatectomy or primary radiotherapy?
Study III: How many working years can women expect to lose due to the diagnosis
and treatment of breast cancer?
Study IV: Which medical causes underlie the increased risk of sick leave and
disability pension receipt in women with breast cancer?
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4 Material and methods
4.1 Study design and data material
This thesis includes 4 population-based cohort studies based on data from the
Prostate Cancer Data Base Sweden (PCBaSe) or the Breast Cancer Data Base
Sweden (BCBaSe). PCBaSe and BCBaSe are research databases that have been
created using individual level record-linkage between quality registers for breast
and prostate cancer and several national demographic and health care registers,
which are described below. PCBaSe includes all men registered in the National
Prostate Cancer Register of Sweden (NPCR), which has nationwide coverage.
BCBaSe includes all women registered in the Breast Cancer Quality Registers of
Stockholm-Gotland, Uppsala-Örebro and the northern regions of Sweden, with a
combined coverage of about 60% of the Swedish population.
Comparison cohorts of cancer-free women and men have also been added to
both the PCBaSe and BCBaSe at a ratio of 1:5. In the PCBaSe, controls were
randomly selected from the Total Population Register using incidence density
sampling, individually matched according to birth year and region of residence. In
the BCBaSe, controls who were breast cancer-free in the year of which the index
case was diagnosed were randomly selected from the Total Population Register,
and individually matched according to sex, birth year, and region of residence. All
controls could later become a case.
4.1.1 Data sources
The National Prostate Cancer Register of Sweden (NPCR)
Since 1998, newly registered cases of prostate cancer from all 6 health care regions
in Sweden have been reported to the NPCR. Beginning in 2008, reporting was
performed using the nationally uniform INCA platform. The completeness of the
NPCR is high, including more than 98% of all men reported to the Swedish Cancer
Register; reporting to the Swedish Cancer Register is mandated by law [120, 121].
The NPCR includes data on prostate adenocarcinomas. The variables registered
include date of diagnosis, birth date, serum PSA, Gleason pattern, clinical stage,
and primary treatment strategy, including surgery type, type of radiotherapy, type
of conservative treatment (active surveillance or watchful waiting), and type of
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hormone therapy [122]. Some information is available for all years, while others
as surgery type and type of conservative treatment is only available from 2007
onward. In the NPCR, only treatment initiated within 6 months after the date
of diagnosis is recorded. Data on subsequent treatment have also been obtained
through additional data collections and linkages with other registers [123].
An evaluation of data quality of 48 variables in the NPCR was performed in
2015 by comparing data in the NPCR to data from medical charts and from other
Swedish registers [121]. The overall agreement was high. For example, it was
observed that for 95% of men with prostate cancer, the information on surgery
type in the NPCR was in exact agreement with data extracted from medical charts.
It was also observed that only 1% of radical prostatectomies recorded in the patient
register were not recorded in the NPCR.
The Breast Cancer Quality Register
The Breast Cancer Quality Register is a population-based register that collects
clinical data on newly diagnosed breast cancer cases. This thesis includes register
data from 3 of the 6 health care regions in Sweden. Since 2008, breast cancer
cases from all 6 regions have been registered through the INCA platform. Similar
to the NPCR, the completeness of the National Breast Cancer Quality Register
is high: 98% of all women with breast cancer registered in the Swedish Cancer
Register are captured by the the National Breast Cancer Quality Register [28].
The Breast Cancer Quality Register includes data on invasive and in situ breast
cancer diagnosed in both women and men. The information collected includes
date of diagnosis, birth date, pre- or postmenopausal status, laterality, clinical
stage, tumor size, tumor grade, ER status, PR status, HER2 status, level of Ki67,
surgery type, and planned adjuvant treatment such as radiotherapy, chemotherapy,
hormone therapy, and HER2-targeted therapy. Before 2008, the set of variables
collected differed between health care regions.
The agreement between planned adjuvant treatments as registered in the
National Breast Cancer Quality Register and initiated adjuvant treatments
extracted from medical charts has been examined in a previous study of 970
women [124]. It was observed that in 94% to 96% of cases, planned adjuvant
treatment corresponded to initiated treatment. In the same study, reasons for
discontinuation of initiated treatment were also examined. For example, 10% of
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women who initiated chemotherapy did not complete the treatment as planned,
with toxicity being the main reason.
The Micro Data for Analysis of Social Insurance Database (MiDAS)
The Micro Data for Analysis of Social Insurance (MiDAS) database is managed
by the Swedish Social Insurance Agency. It contains data on all periods of sick
leave and disability pension compensated by the Social Insurance Agency since
1994 [125]. The variables included are start and end dates, type of compensation,
degree of compensation (25%, 50%, 75%, or 100%,) and the main and secondary
underlying diagnosis reported by the certifying physician according to the
International Classification of Diseases (ICD) version 9 or 10. For data on sick
leave, information on diagnosis is only considered to be satisfactorily recorded
starting in 2005, and there is no information on the secondary diagnosis. Since
days 2 to 14 of a sick leave period are usually paid by the employer, the database
contains little to no information on sick leave periods 14 days or shorter.
While no published studies to date have examined the quality of data in MiDAS,
data based on payments are generally considered accurate. In the early 1990s, a
Swedish study assessed the quality of diagnoses for sick leave in a regional sick-
leave register [126]. In that study, it was observed that for 50% of the cases, the
diagnosis code in the register corresponded exactly to the diagnosis code input by
a general practitioner after review of the medical records. When the whole group
of diseases to which the diagnosis belonged was considered instead, the match
increased to 80%.
The Longitudinal Integration Database for Health Insurance and Labor Market
Studies (LISA)
The Longitudinal Integration Database for Health Insurance and Labor Market
Studies (LISA) is a database kept at Statistics Sweden. Since 1990, it has integrated
administrative data from the labor market, and the educational and social sectors
[127]. It includes information on marital status, education level, socioeconomic
index, vocational code, employment status, welfare benefits, and income for all
individuals in Sweden aged 16 and older. The data in LISA are generally for a
specific calendar year.
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The Income and Taxation Register
The Income and Taxation Register, kept by Statistics Sweden, also contains
information on income [128]. In addition to income from work, other types of
allowances are also registered, such as old-age pension.
The Total Population Register
The Total Population Register was established in 1968 and is kept by Statistics
Sweden. It includes data on place of residence and in- and out-migration from
Sweden. There is a concern about over-coverage in this register, since not all
individuals report emigration. The over-coverage has been estimated to be 0.25%
to 0.5% of the Swedish population [129].
The Patient Register
The Patient Register is administered by the National Board of Health and Welfare
[130]. Since 1987, it has contained records of inpatient care with hospital discharge
diagnoses from all hospitals in Sweden. One main discharge diagnosis and up to 8
additional diagnoses are recorded according to the ICD. Around 1% of all records
lack information as to the main medical diagnosis, and up to 2% lack information
on patient identity. A large number of studies validating the information in the
patient register have been performed, most reporting that 85% to 95% of diagnoses
in the patient register correspond to diagnoses in medical charts [131]. Since
2001, the Patient Register has also included records of specialized outpatient care.
During the first years, up to 25% to 30% of all records lacked information on the
primary diagnosis, a figure that was reduced to 4% by 2016 [130]. Almost all
public health care providers report to the outpatient register, but not all private
providers. The register’s geographical coverage has been estimated to be around
80% [131].
The Swedish Prescribed Drug Register
Since July 2005, the Swedish Prescribed Drug Register, kept by the National
Board of Health and Welfare, has collected individual-level information on all
prescriptions dispensed in Swedish pharmacies [132]. The register includes
information such as drug name, amount, dose, and prescription and dispensing
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dates. Less than 0.3% of all dispensed prescriptions lack information on patient
identity. Drugs dispensed for inpatient hospital care and non-prescribed drugs are
not included in the register.
The Cause of Death Register
The Cause of Death Register is kept by the National Board of Health and Welfare
and includes information on date and cause of death as reported by a physician on
the medical death certificate [133]. The register is virtually complete with respect
to number of deaths, and information on the specific cause of death is available for
96% of all deaths.
4.1.2 Ethical considerations using register data
The use of register-based data is regulated in Swedish law by the Public Access
and Secrecy Act (Offentlighets- och sekretesslagen), the General Data Protection
Regulation (Dataskyddsförordningen and Dataskyddslagen), and the Ethical
Review Act (Etikprövningslagen). Health-related data are considered sensitive,
and may only be used in certain circumstances. They may be used for research
purposes if data protection principles—for example, by approval from an Ethical
Review Board—are met. All studies in this thesis have been approved by the
Ethical Review Board in Umeå or Stockholm. An exception to the requirement of
informed consent was granted due to the large number of involved study
participants. Other measures taken to protect the confidentiality of study
participants were secure databases, de-identification of data for analyses, and
presentation of results only on an aggregated level without possibility to
backtrace.
4.2 Study populations
Studies I and II were based on men identified in the PCBaSe and studies III and IV
on women identified in the BCBaSe. All studies included a matched comparison
cohort of breast and prostate cancer-free women and men.
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Men aged < 64 years treated with radical prostatectomy 
between 2007 and 2009 
n = 3,381
Excluded:
Laparoscopic prostatectomy, n = 166 
Unclear type of surgery, n = 6
Excluded:
Social welfare, n = 31 
Disability pension, n = 340
Long-term sick leave, n = 112
Early old-age retirement, n = 155 
RARP or RRP
n = 3,209
Eligible for sickness benefits
n = 2,571 
Figure 4.1: Flowchart Study I
4.2.1 Study I
Study I included all men diagnosed with non-metastatic prostate cancer (T1–T3,
N0, M0, and PSA < 50 µg/l) under the age of 64 years treated with retropubic or
robot-assisted radical prostatectomy between January 1, 2007 and December 31,
2009. Exclusion criteria were being on long-term sick leave at the time of surgery
(beginning 2 months or more prior to surgery), receipt of disability pension prior
to surgery, and receipt of old-age pension benefits or social welfare in the year
prior to surgery. After applying these exclusion criteria to both men with and men
without prostate cancer, the study population consisted of 2,571 men with prostate
cancer (Figure 4.1) and 9,483 matched prostate cancer-free men.
4.2.2 Study II
Study II included men diagnosed with localized low-risk (T1—T2, GGG 1, and
PSA < 10 µg/l) or intermediate-risk (T1—T2, GGG 2 or 3, and/or PSA 10 to < 20
µg/l) prostate cancer under the age of 64 years. Men diagnosed between January
1, 2007 and December 31, 2012 and treated with either active surveillance, radical
prostatectomy or radiotherapy were included. Exclusion criteria were being on sick
leave 1 month prior to diagnosis, receipt of disability pension prior to diagnosis,
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Men aged < 64 years with low or intermediate risk prostate
cancer diagnosed between 2007 and 2012 
n = 11,335 
Excluded:
Other treatment, n = 335  
Unclear treatment, n = 369 
Excluded:
Sick leave, n = 293 
Disability pension, n = 1,197
Other reason for not working, n = 442
Active surveillance, surgery or
radiotherapy
n = 10,631
Working at diagnosis
n = 8,699 
Figure 4.2: Flowchart Study II
and not working (i.e. no gainful employment) in the year prior to diagnosis. The
final study population consisted of 8,699 men with prostate cancer (Figure 4.2)
and 34,189 matched prostate cancer-free men.
4.2.3 Study III
Study III included women with in situ and invasive breast cancer of all stages
diagnosed between January 1, 1997 and December 31, 2012 and aged 60 years or
younger at diagnosis. Because data on old-age pension (which can be obtained
starting at age 61) was only available beginning in 2003, women aged 56–60 years
were only included if they were diagnosed between January 1, 2003 and December
31, 2012. Exclusion criteria were receipt of disability pension (≥ 75%) prior to
diagnosis, no income from work in the year prior to diagnosis, and receipt of
old-age pension in the year of diagnosis. The final population consisted of 19,661
women with breast cancer (Figure 4.3) and 81,303 breast cancer-free women.
4.2.4 Study IV
Study IV included women with stage I to stage III breast cancer aged 30 to 64
years at diagnosis who were diagnosed between January 1, 2000 and December 31,
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Women aged < 61 years diagnosed with breast cancer
between 1997 and 2012 
n = 23,231
Excluded:
Disability pension (≥ 75%), n = 2,235 
Early old-age retirement, n = 19
No income from work, n = 1,316 
Working at diagnosis
n = 19,661
Figure 4.3: Flowchart Study III
2012. Analyses of sick leave were restricted to women diagnosed in 2005 or later.
Women with stage IV breast cancer were not included due to strong competing
events for some of the outcomes under study. Exclusion criteria were being on sick
leave 1 month prior to diagnosis and receipt of disability pension prior to diagnosis.
The final study population consisted of 16,603 women with breast cancer (Figure
4.4) and 63,773 breast cancer-free women.
4.3 Exposures
In all studies, the exposures were related to diagnosis and treatment of breast or
prostate cancer.
4.3.1 Studies I and II
In Studies I and II, the exposure was type of radical prostatectomy (retropubic or
robot-assisted radical prostatectomy) or type of treatment strategy (active
surveillance, radical prostatectomy, or radiotherapy), extracted primarily from the
NPCR. In Study I, information in the Patient Register was used to identify
surgeries performed 6 months or later after diagnosis (which are not reported to
the NPCR), or if information on surgery type was missing (7 out of 36 hospitals
started to report surgery type starting in 2008). In one hospital (Karolinska
University Hospital), all surgeries with missing information were coded as
robot-assisted, which was the procedure used for 99% of men in this age group
during the study period.
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Women aged 30-64 years diagnosed with breast cancer
between 2000 and 2012 
n = 23,759
Excluded:
Stage IV, n = 506 
Unknown stage, n = 1,396 
Excluded:
Sick leave, n = 1,507 
Disability pension, n = 3,747
Stage I-III breast cancer
n = 21,857
No sick leave or disability
pension at diagnosis
n = 16,603
Figure 4.4: Flowchart Study IV
4.3.2 Studies III and IV
In Studies III and IV, the exposures of primary interest was breast cancer and stage
of breast cancer, extracted from the Breast Cancer Quality Registers. Disease
stage was defined according to the 7th edition of the American Joint Committee
on Cancer TNM classification [134]. The T-stage and N-stage were extracted from
information based on the pathology report when no neo-adjuvant treatment was
given; otherwise, information from clinical examination was used. The clinical
N-stage was also used if it was higher than the pathological N-stage.
4.4 Outcomes and follow-up
The primary outcomes in all studies are related to sick leave and disability pension
receipt as granted by the Swedish Social Insurance Agency. Since the employer
usually compensates the first 2 to 14 days of a sick leave period, only sick leave
periods longer than 14 days are included in this thesis. However, the date of the
first day of sick leave is available in MiDAS, and this date has been defined as
the start date of sick leave in all studies. All types and degrees of sick leave
and disability pension receipt were included, unless otherwise stated. Disability
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pension receipt was considered to be a permanent absence from the labor market
[135].
4.4.1 Study I
In Study I, we defined two outcomes: 1) time to return to work after surgery
(duration of sick leave) and 2) days lost from work due to sick leave and disability
pension receipt after return to work. Return to work was defined as the last date
of the sick leave period that was ongoing or started within 30 days after the date
of surgery. Sick-leave periods that started within 5 days after the end date of a
previous sick leave period were considered a continuation of the previous period.
In the analysis of the second outcome, men were followed from the date of
return to work after surgery until age 65, death, emigration, or end of follow-up
(31 December 2012). Men with no registered sick leave were followed from the
date of surgery. Prostate cancer-free comparison men were at risk from the date
of return to work of their matched case. Men who did not return to work (n = 10)
were not included in the analysis of the second outcome.
4.4.2 Study II
In Study II, the outcomes were sick leave and disability pension receipt. The
competing event death was also included in the analysis. All-cause and cause-
specific sick leave, disability pension receipt, and death were studied; causes of
interest were prostate cancer (ICD-10 code C61), and depression, anxiety, and
stress-related conditions (F32–F34, F38–F43, F45, F48). Periods with sick leave
that ended within one month of a new event were not considered return to work.
Men were followed from the date of diagnosis until age 65, death, emigration, or
end of follow-up (31 December 2014).
4.4.3 Study III
In Study III, the outcome was permanent exit from the labor market, defined as
receipt of disability pension (≥ 75%), old-age retirement, or death. Since we did
not have information on the exact time-point of old-age retirement, it was defined
as the year when the annual income from the old-age pension obtained starting
at age 61 exceeded the annual income from pensionable earnings. Women were
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followed from diagnosis until permanent exit from the labor market, reaching age
65, emigration, or end of follow-up (31 December 2012). In a sensitivity analysis,
we examined another definition of permanent exit from the labor market, defined
as the year when the annual income from labor earnings decreased to zero. A
separate analysis examining net number of days on sick leave in the first 3 years
after diagnosis was also conducted.
4.4.4 Study IV
In Study IV, the outcomes were sick leave and disability pension receipt attributed
to the following causes: cancer, mental disorders (i.e., depression, anxiety, and
stress-related disorders), musculoskeletal disease, cardiovascular disease,
inflammatory disease, fatigue, pain or insomnia, and lymphedema-related
diagnoses (ICD-codes are listed in Supplementary Table 1 of Study IV). The
competing event death was also included. Periods with sick leave that ended
within one month of a new event were not considered return to work. Women
were followed from diagnosis to age 65, death, emigration, or end of follow-up
(December 31, 2013).
4.5 Covariates
In all 4 studies, included covariates belong to 3 broad categories: demographic
and sociodemographic characteristics, health-related characteristics, and tumor
and treatment characteristics. Covariates were mainly treated as confounders, and
in studies II and IV some were also considered to be mediators. Confounders
were measured before diagnosis and treated as time-constant, whereas mediators
were measured after diagnosis and treated as time-varying. Depending on the aim
and the method used in the study, we included some or all of the covariates listed
below.
The demographic and sociodemographic variables included were age at
diagnosis or surgery, calendar year of diagnosis, region of residence, highest level
of education, disposable income, employment status, and occupation.
Occupations were classified by skill levels according to the International Standard
Classification of Occupations 2008 (ISCO-08) [136]. Age was included either as
a categorical variable or as a continuous variable using restricted cubic splines.
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Health-related variables prior to diagnosis or surgery were sick leave and
comorbidities, the latter of which was based on hospitalizations in the Patient
Register and further classified using the Charlson Comorbidity Index [137]. The
Patient Register was also used to obtain information on cause-specific medical
events after diagnosis, which were treated as mediators in Study IV.
In the studies of prostate cancer, tumor and treatment-related variables were
risk category, lymph node dissection, type of hospital, and secondary treatment
(secondary treatment was treated as a mediator in Study II). In the studies of breast
cancer, variables included were tumor size, ER status, lymph node involvement,
surgery type, type of axillary surgery, radiotherapy, chemotherapy, and endocrine
treatment.
4.6 Statistical methods and measures
Survival analysis or, more generally, time-to-event analysis was the main statistical
method in all 4 studies. An overview of the statistical methods used in this thesis
is presented in Table 4.1.
Table 4.1: Statistical analyses used in this thesis
Study Statistical analysis
I Cox proportional hazards regression, Generalized Estimating Equations
(GEE) Poisson regression
II Non-parametric multi-state modeling
III Flexible parametric survival analysis
IV Non-parametric and flexible parametric multi-state modeling
4.6.1 Generalized Estimating Equations (GEE) Poisson regression
In Study I, we used Generalized Estimating Equations (GEE) Poisson regression
to model days lost from work due to sick leave and disability pension receipt.
GEE makes no assumption about the underlying distribution and uses robust
standard errors (which do not assume equal variance across observations) to
obtain confidence intervals. It is a common method for analyzing clustered data
(the data in Study I were not treated as clustered). We included an over-dispersion
parameter and an offset variable in the analysis, taking into account that not all
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individuals were followed for the same period of time. Days lost from work were
modeled as a rate, i.e., number of days lost per person-year.
4.6.2 The Cox proportional hazards model
In Study I, Cox proportional hazards regression was used to examine the
association between return to work and surgery type for prostate cancer, with time
since surgery as the underlying time scale. As with most other time-to-event
methods, this is a model for the hazard rate, which is the instantaneous rate of
having the event at time t. The effect measure obtained is the hazard ratio. In a
Cox model, it is assumed that the hazard ratio remains constant over time,
although this assumption can be relaxed by splitting follow-up time and including
interaction terms, as was done in Study I. As with other time-to-event methods,
unequal follow-up time is accounted for by censoring. Right censoring is the most
common type of censoring, and occurs if, for example, a study participant is
followed for the whole study period without experiencing the event. Cox models
are semi-parametric, meaning no assumptions are made regarding the shape of the
baseline hazard rate.
4.6.3 Flexible parametric survival analysis
In contrast to the semi-parametric Cox model, fully parametric models estimate
the baseline hazard rate. The advantage of this is that measures of absolute effects
can be obtained and time-dependent effects are more easily modeled. Flexible
parametric models are, as the name implies, more flexible in capturing the shape
of the baseline hazard than standard parametric models such as the Weibull model
[138]. The flexibility is attained through the use of restricted cubic splines, with
the number of join points or knots specified by the researcher. The number of knots,
or rather the degrees of freedom (the number of knots minus 1), are chosen both
for modeling of the baseline hazard function and for modeling of time-dependent
effects. In Study III, the baseline hazard function was modeled with 5 degrees of
freedom and the time-dependent effect of age at diagnosis and disease stage with
2 degrees of freedom. In Study IV, the Akaike Information Criterion (AIC) guided
the choice of degrees of freedom [139], which was from 3 to 5 for the baseline
hazard function and 1 to 3 for the time-dependent effect of breast cancer.
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4.6.4 Competing risks
In the presence of competing events, cause-specific hazard ratios can be estimated
using standard survival analysis as described above, and directly interpreted as
long as the competing event is censored for. However, to account for competing
risks rather than censoring them, the cause-specific cumulative incidence function
(CIF) must be used [140]. The cause-specific CIF is the proportion of individuals
who have experienced an event as a function of time, taking into account that it
is impossible to experience an event if a competing event happened first. The
probability of having any event is the sum of all cause-specific CIFs at a certain
time. The CIF can be computed non-parametrically or after fitting a regression
model for survival data [141, 142], as was done in Study III.
4.6.5 Multi-state survival analysis
Multi-state models are an extension of standard survival analysis, and allow for
the inclusion of both recurrent events and related, possibly competing events in
the same framework. The standard survival analysis can be viewed as a multi-state
model with two states: alive (initial state) and dead (absorbing state); the change
from alive to dead is called a transition. Survival analysis with competing risk
is also a type of multi-state model, with two or more absorbing states. Further
states and transitions can be added, including intermediate states. Figure 4.5
illustrates the multi-state models used in this thesis, with arrows representing
possible transitions. In Studies II and III, we studied cause-specific sick leave,
disability pension receipt, and death, as illustrated in Figure 4.6. In Study II,
we further extended the multi-state model to include separate sick leave states for
being on initial treatment strategy as opposed to having received secondary therapy
(Figure 4.7).
The multi-state models used in this thesis are Markov models, which are
stochastic models describing the sequence of events [140, 143]. The underlying
assumption is that the probability of transition to the next state is only dependent
on the current state and time since origin, but not on the previous history of
transitions. One situation in which the Markov assumption does not hold is when
the length of stay in a state influences the transition to the next state; in such cases,
semi-Markov models have been proposed, in which the time scale is time since
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Figure 4.5: Multi-state models in this thesis
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Figure 4.6: Cause-specific multi-state model (Studies II and IV)
Sick leave secondary treatment
Sick leave initial treatment
Work
Disability pension Death
Figure 4.7: Multi-state model with different sick leave states according to treatment
status (Study II)
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entry into last state. Competing risk models are always Markovian (no previous
history of events).
The Markov model is fully characterized by transition hazards (e.g., the
instantaneous rate of entering state 2 from state 1 at time t) or by transition
probabilities (e.g., the probability of entering state 2 at time t from state 1 at time
s). A matrix of transition probabilities can be estimated non-parametrically using
the Aalen-Johansen estimator, which is a matrix version of the Kaplan-Meier
estimator [143]. From the matrix, transition probabilities and state occupancy
probabilities can be obtained, the latter of which is the probability of being in a
state at a certain time (equivalent to the transition probability if all individuals
start in an initial state at time 0). In a competing risks model, transition
probabilities are the same as the CIF. An important notion is that if the
assumption of independent censoring holds, state occupancy probabilities
obtained through the Aalen-Johansen estimator have also been found to be
consistent estimators for non-Markov models [144].
In both Study II and Study IV, the Aalen-Johansen estimator was used to estimate
and plot transition probabilities, with time since diagnosis as the underlying time
scale. Other measures that can be obtained from a multi-state model are the
probability of ever visiting a state and expected length of stay, which is the mean
amount of time spent in a state between two time points. In Study II, length of
stay was obtained by integration, whereas the probability of ever visiting a state
was obtained by simulation, similar to the procedure described below. Confidence
intervals were obtained by bootstrap resampling.
Since a multi-state model is characterized by a combination of
transition-specific hazards, estimation can also be performed by fitting
semi-parametric or fully parametric regression models. These regression models
have the advantage that covariate-adjusted estimates can be obtained. Recently, a
framework for flexible parametric multi-state modeling allowing for
transition-specific distributions was presented by Crowther and Lambert [145].
Within this framework, which was used in Study IV, a model of choice is fitted for
each transition in the multi-state model, including covariates and time-dependent
effects as appropriate. Based on estimated coefficients from the fitted models, a
simulated data set is then generated, from which transition probabilities and other
measures can be calculated. Quantities of interest are either obtained for a specific
covariate pattern or averaged (standardized) over the covariate distribution.
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4.6.6 Work-life expectancy
Work-life expectancy is defined as the time spent working until retirement, given
a certain age. The idea as such is not new, where economists have had an interest
in work-life expectancy for a long time [146], but it has received only a small
amount of attention in the field of public health and medicine [147]. Work-life
expectancy is conceptually equivalent to life expectancy; the only difference is
that life expectancy quantifies survival over the entire life span, whereas work-life
expectancy is restricted to retirement (usually the age of 65). Restricted mean
survival time is a more general term for work-life expectancy [148, 149].
Multi-state models are ideal models for estimating work life expectancies, where
length of stay is an extension of restricted mean survival time [145]. For example,
in the multi-state models illustrated in Figure 4.5, the work-life expectancy is
the average time spent in the working state until retirement. We obtain loss of
work-life expectancy (referred to as loss in working years in Study III) due to,
for example, breast cancer, by calculating the difference in the time spent in the
working state between women of the same age with and without breast cancer. This
measure is a useful and easily interpretable summary measure from the often quite
complex multi-state model. A measure of work-life expectancy has explicitly been
used in Study III, but studies II and IV also include measures related to work-life
expectancy (e.g., length of stay in work within the first 5 years after diagnosis).
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5 Main results
5.1 Study I
Study I examined the influence of surgery type for prostate cancer on return to
work and long-term work disability in 1,062 men treated with robot-assisted
radical prostatectomy and 1,509 men treated with retropubic radical
prostatectomy between 2007 and 2009. During this period, 9 out of 43 hospitals
in Sweden performed robot-assisted radical prostatectomy (Figure 5.1).
Robot-assisted surgery was associated with an earlier return to work. Of men
treated with robot-assisted surgery, 22% did not have a period of sick leave > 14
days after the surgery, compared with 12% of men treated with open surgery. The
median time to return to work in men with sick leave > 14 days was 35 days
(interquartile range [IQR], 8 to 52) after robot-assisted radical prostatectomy,
compared with 48 days (IQR, 39 to 68) after retropubic radical prostatectomy.
After adjustment for age, risk category, lymph node dissection, income, education,
occupation, and prior sick leave, the overall hazard ratio of return to work
comparing men who had undergone robot-assisted surgery with men treated with
open surgery was 1.51 (95% CI, 1.38 to 1.66). Because the assumption of
non-proportional hazards was not fulfilled, interval-specific hazard ratios were
generated (Table 5.1).
Table 5.1: Hazard ratios and 95% confidence intervals of return to work
Surgery type Time period HR (95% CI)
Retropubic 1.00 (Ref.)
Robot-assisted Overall 1.51 (1.38–1.66)
Month 0–1 3.76 (3.04–4.66)
Month 1–2 1.35 (1.19–1.53)
Month 2–3 0.94 (0.73–1.20)
Month 3–6 0.98 (0.68–1.42)
Month 6–12 0.83 (0.47–1.48)
In addition to what is presented in the paper, we predicted the average time
spent on sick leave from a flexible parametric survival model including the same
confounders specified above. In that analysis, men treated with robot-assisted
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Hospital without robot
Hospital with robot
Figure 5.1: Hospitals performing radical prostatectomies in Sweden 2007–2009
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surgery spent on average 37 days (95% CI, 34 to 40) on sick leave, as compared
with 48 days (95% CI, 45 to 51) in men treated with open surgery.
We also examined the number of days lost from work due to sick leave and
disability pension receipt after return to work. During a median follow-up of 3.6
years, men treated with robot-assisted surgery lost 12 days, and men with open
surgery 15 days per person-year. After adjustment, surgery type was not associated
with increased rates of sick leave and disability pension receipt (rate ratio 1.08;
95% CI, 0.82 to 1.42).
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5.2 Study II
Study II examined the influence of choice of treatment modality for localized
prostate cancer on days lost from work due to sick leave, disability pension
receipt, and death in 8,699 men with low- or intermediate-risk prostate cancer
diagnosed between 2007 and 2012, and 34,189 matched prostate cancer-free men.
The percentage of men in each treatment strategy by year of diagnosis is
presented in Table 5.2.
Table 5.2: Percentage of men in each treatment strategy by year of diagnosis
Treatment strategy 2007 2008 2009 2010 2011 2012
Active surveillance 20% 21% 24% 27% 31% 34%
Radical prostatectomy 67% 65% 63% 61% 60% 57%
Radiotherapy 13% 14% 13% 12% 10% 10%
The proportion of men on sick leave varied strongly by treatment strategy and
time since diagnosis (Figure 5.2). In the group of men treated with surgery or
radiotherapy, the proportion of men on sick leave was highest in the first year of
diagnosis, with single-time point proportions of up to 30%. The probability of
having at least 1 period with sick leave in the first year of diagnosis was 65% in
men treated with surgery, and 45% in men who underwent radiotherapy. In men
with active surveillance as the primary treatment strategy, the proportion of men
on sick leave was low (2% to 5%) throughout the study period. Five years after
diagnosis, the proportion of men free from sick leave, disability pension receipt
and death was 95% in men on active surveillance, 93% in men treated with radical
prostatectomy, and 92% in men treated with radiotherapy. The corresponding
proportion in prostate cancer-free men was 94%.
We also calculated length of stay on work, sick leave, disability pension receipt,
and death in the first 5 years after diagnosis. In all treatment strategies, the majority
of time was spent in the working state. The average time spent on prostate cancer-
specific sick leave was lowest in men on active surveillance (16 days; 95% CI, 14
to 18), the vast majority of which was spent by men with subsequent conversion
to radical therapy. The number of days on prostate cancer-specific sick leave was
considerably higher in men treated with primary radical prostatectomy (48 days;
95% CI, 45 to 50) or primary radiotherapy (44 days; 95% CI, 37 to 50). The time
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Figure 5.2: Proportion of men on sick leave, disability pension receipt, and death
by initial treatment strategy. Abbreviations: AS, active surveillance; PCa, prostate
cancer; RT, radiotherapy; RP, radical prostatectomy
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spent on sick leave due to depression, anxiety, and stress was also lowest in men
on active surveillance. When also taking other causes of sick leave, as well as
disability pension receipt and death into account, men on active surveillance lost
21 days (95% CI, 20 to 21) from work compared with prostate cancer-free men. In
men treated with radical prostatectomy, the corresponding loss was 45 days (95%
CI, 45 to 46), and in men treated with radiotherapy, 72 days (95% CI, 71 to 73).
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5.3 Study III
Study III examined the loss of work-life expectancy (loss in working years) due to
breast cancer and associated treatments in 19,661 women diagnosed with breast
cancer between 1997 and 2012, and 81,303 matched breast cancer-free women.
Of the women included, 2,218 (11%) had in situ, 7,301 (37%) stage I, 6,535 (33%)
stage II, 2,197 (11%) stage III, and 340 (2%) stage IV breast cancer. In 1,070 (5%)
women, no information on disease stage was available.
The loss in working years due to disability pension receipt, early old-age
retirement, and death varied by age at diagnosis, disease stage, and treatment type.
It was highest in women with stage IV breast cancer, among whom women aged
50 years at diagnosis lost on average 8.1 years (2,967 days) (Table 5.3). In
contrast, women with stage I breast cancer who where also aged 50 years at
diagnosis lost on average 0.5 years (166 days).
Table 5.3: Loss in working years due to breast cancer in women aged 50 years at
diagnosis
Stage Loss in working years (95% CI)
In situ -0.1 (-0.5 to 0.4)
Stage I 0.5 (0.2 to 0.7)
Stage II 0.9 (0.5 to 1.2)
Stage III 2.5 (1.9 to 3.1)
Stage IV 8.1 (6.5 to 9.7)
Some groups of women, including women with in situ breast cancer and
women with stage I breast cancer treated with breast-conserving surgery,
radiotherapy, chemotherapy, and endocrine therapy, had no loss in working years.
Chemotherapy and mastectomy were generally not associated with a loss in
working years, whereas axillary lymph node dissection was. Figure 5.3 illustrates
the probability of exit from the labor market by primary reason for exit and
treatment type in women aged 55 years at diagnosis with stage I breast cancer.
51
0.0
0.2
0.4
0.6
0.8
1.0
0 5 10
Years since diagnosis
Pr
ob
ab
ilit
y 
of
 e
xi
t
Breast−conserving surgery
0.0
0.2
0.4
0.6
0.8
1.0
0 5 10
Years since diagnosis
Pr
ob
ab
ilit
y 
of
 e
xi
t
Mastectomy
Old−age retirement
Disability pension
Death
0.0
0.2
0.4
0.6
0.8
1.0
0 5 10
Years since diagnosis
Pr
ob
ab
ilit
y 
of
 e
xi
t
SNB
0.0
0.2
0.4
0.6
0.8
1.0
0 5 10
Years since diagnosis
Pr
ob
ab
ilit
y 
of
 e
xi
t
ALND
Old−age retirement
Disability pension
Death
0.0
0.2
0.4
0.6
0.8
1.0
0 5 10
Years since diagnosis
Pr
ob
ab
ilit
y 
of
 e
xi
t
No chemotherapy
0.0
0.2
0.4
0.6
0.8
1.0
0 5 10
Years since diagnosis
Pr
ob
ab
ilit
y 
of
 e
xi
t
Chemotherapy
Old−age retirement
Disability pension
Death
Figure 5.3: Probability of exit from the labor market by primary reason for exit and
treatment type. Abbreviations: ALND, axillary lymph node dissection; SNB, sentinel
node biopsy
52
5.4 Study IV
Study IV assessed the risk of cause-specific sick leave and disability pension
receipt in women with breast cancer compared with breast cancer-free women.
The study population was partly the same as in Study III, and included 16,603
women with stages I to III breast cancer diagnosed between 2000 and 2012, and
63,773 matched breast cancer-free women.
Cancer was the most commonly reported cause of both sick leave and disability
pension receipt in women with breast cancer (Figure 5.4). In the first year of
diagnosis, 80% of women had at least 1 period of sick leave attributed to cancer.
One year after diagnosis, 26% of women were on sick leave because of cancer,
and 3% due to other reasons. Five years after diagnosis, the proportion of women
on sick leave due to cancer had decreased to 3%, similar to the proportion on sick
leave due to other reasons (4%). The proportion of women on disability pension
was low: less than 3% of women were on disability pension 5 years after diagnosis.
The corresponding proportion at year 10 after diagnosis was 11%.
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Figure 5.4: Proportion of women on sick leave, disability pension and death by type
of modeling
Compared with breast cancer-free women, women with breast cancer had up
to a 100-fold increased risk of sick leave and disability pension receipt due to
cancer. Metastatic disease was a strong contributing factor, but other conditions,
including mental disorders, were also identified as contributors. The most common
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secondary diagnoses for disability pension attributed to breast cancer are presented
in Table 5.4 (27% of women had a secondary cause registered).
Table 5.4: The 10 most common secondary causes of disability pension attributed to
breast cancer
ICD-10 code Disease n (%)
F32 Depressive episode 15 (9)
I97 Postprocedural disorders of circulatory system, not
elsewhere classified
14 (9)
C79 Secondary malignant neoplasm of other and unspecified
sites
13 (8)
F43 Reaction to severe stress, and adjustment disorders 13 (8)
C78 Secondary malignant neoplasm of respiratory and
digestive organs
9 (6)
M54 Dorsalgia 8 (5)
M25 Other joint disorders, not elsewhere classified 7 (4)
F41 Other anxiety disorders 5 (3)
M50 Cervical disc disorders 3 (2)
M53 Other dorsopathies, not elsewhere classified 4 (2)
Despite the strong competing risk of cancer-specific absence from work, we also
observed an increased risk of both sick leave and disability pension receipt due
to mental disorders (Table 5.5). The absolute risk increase, however, was low: In
the first 5 years, women with breast cancer spent on average 17 days (95% CI, 14
to 18) on sick leave due to mental disorders, as compared with 16 days (95% CI,
14 to 17) in breast cancer-free women. Mastectomy was the only clinical factor
significantly associated with an increased risk of disability pension receipt due to
mental disorders. We also observed an increased risk of disability pension due to
inflammatory and cardiovascular diseases.
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Table 5.5: Adjusted hazard ratio of sick leave and disability pension receipt
comparing women with breast cancer with breast cancer-free women
Disease group HRSick leave (95% CI) HRDisability pension (95% CI)
Cancer 97.3 (90.6–104.5) 53.6 (40.6–70.7)
Mental disorders 1.24 (1.15–1.33) 1.54 (1.29–1.85)
Musculoskeletal diseases 0.86 (0.80–0.93) 1.13 (0.95–1.34)
Cardiovascular diseases 1.21 (0.97–1.49) 1.45 (0.98–2.15)
Inflammatory diseases 0.80 (0.63–1.02) 1.46 (1.05–2.03)
55
56
6 Discussion
6.1 Summary of findings
Our findings show that around 60% to 80% of men who underwent surgery for
prostate cancer had at least 1 period of sick leave longer than 14 days after the
procedure. The duration of absence was related to surgery type; we found that men
treated with robot-assisted radical prostatectomy returned to work earlier than men
treated with retropubic radical prostatectomy, also after adjusting for factors such
as risk category, education, and income. In contrast to prostate cancer surgery,
active surveillance had only a slight impact on sick leave. During the first 5 years
after diagnosis, men with active surveillance as the primary treatment strategy had
less than half as many days on prostate cancer-specific sick leave as men treated
with radical prostatectomy or radiotherapy. The type of primary treatment strategy
had little to no influence on long-term sick leave and disability pension receipt.
In women with breast cancer, 80% had at least one longer period with sick leave
in the first year of diagnosis. The amount of time lost from work in subsequent
years was strongly associated with disease stage at diagnosis. Women aged 50
years at diagnosis with stage I breast cancer lost on average half a year of their
remaining working time, in contrast to women with stage IV disease, who lost
over 8 years. Treatment type also had an influence, especially axillary lymph
node dissection, which increased the risk of receiving disability pension both in
all-cause and cause-specific analyses. Our findings from cause-specific analyses
indicate that adverse events due to breast cancer treatment have an impact on
permanent absence from work. Women with breast cancer had an increased risk of
sick leave and/or disability pension receipt due to nearly all of the studied disease
groups, including mental disorders, cardiovascular disease, inflammatory diseases,
fatigue-related conditions, and lymphedema.
6.2 Methodological considerations
The findings presented in this thesis should be viewed in relation to possible
sources of error. In epidemiological research, errors are broadly categorized into
how individuals are selected (selection bias), how variables are measured
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(measurement bias), the presence of common causes shared by exposure and
outcome (confounding), and random variability [150].
6.2.1 Selection bias
The major strength of the studies in this thesis was the use of population-based,
mostly national, demographic and health care registers with virtually complete
geographical coverage, which minimizes the risk of selection bias. In addition,
follow-up through nationwide registers reduces bias arising from differential loss
to follow-up. Individuals who emigrate out of Sweden can be thought of as lost to
follow-up, a proportion that was low (< 1%) in the included studies. Selection bias
may also be caused by restricting the analysis to individuals with complete follow-
up; for example, those who have not died [150]. In the present thesis, estimates
of the competing event death are simultaneously reported to illustrate the overall
impact of cancer on working life.
6.2.2 Measurement bias
The registers used to obtain data for the purpose of this thesis are considered
to have high validity in terms of included variables, which reduces the risk of
measurement bias. Because variables were recorded prospectively, any errors in
the measurement of exposure are unrelated (nondifferential) to the outcomes under
study. We had an issue with misclassification of the exposure in Study I: because
surgery type was not available in the NPCR for all hospitals and all years, we
had to rely on data from the Patient Register. While conducting the study, we
discovered that some of the robot-assisted surgeries had been reported as open
surgeries in the Patient Register. Although we were able to partly account for
this, such a misclassification would bias the relative risk estimates toward the null
hypothesis.
Measurement errors of the outcomes may be differential with respect to the
exposure. For example, women with breast cancer may be more closely monitored
than women without breast cancer, and physicians may record medical events in a
different way. The increased contact with health care providers among women with
breast cancer might also increase the likelihood of being sick-listed, although the
underlying medical condition may be of equal severity compared with cancer-free
women. We cannot rule this out as a contributing factor for the increased risk of
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sick leave and disability pension receipt observed in women and men with cancer.
However, cancer-specific sick leave and disability pension receipt should be less
affected by such a bias, simply because we are more certain that the underlying
cause is related to cancer and cancer treatment.
In all studies, there was a risk of misclassification of outcomes due to lack of
data. Sick-leave periods under 15 days are not recorded in the database kept by the
Swedish Social Insurance Agency. As a result, presented proportions of sick leave
are likely an underestimate of the true proportion of women and men on sick leave,
and we have overestimated the proportion remaining in work. This is true for both
the cancer and the comparison cohort. However, it is unclear whether the degree
of underestimation is related to the diagnosis and treatment of cancer, and whether
the estimates involving the comparison group are affected. In Studies I and III, we
performed sensitivity analyses to examine the effect of potential misclassification
of the outcomes, for which results in general were in agreement with results from
main analyses.
With the exception of Study III, the studies did not include absence from work
due to unemployment or old-age retirement before the age of 65 years. In our multi-
state model, individuals who are unemployed or take early retirement pension are
considered to be available for work, and remain in the working state unless they
transition to sick leave, disability pension receipt, death, or are censored. Thus, the
working state consists of both individuals who are truly working and individuals
who are absent from work due to any other reasons than the one under study.
Another issue was the lack of data on all of the underlying medical diagnoses
for sick leave and disability pension receipt. While we have no reason to question
that the registered cause was an underlying reason for sick leave or disability
pension receipt, we lacked information on contributing reasons, since MiDAS
only contains 1 diagnosis for sick leave (up to 2 diagnoses are recorded for
disability pension receipt). This is particularly problematic when the registered
cause is “breast cancer” or “prostate cancer”: is the underlying reason ongoing
treatment for cancer, cancer progression, or a treatment-related adverse event?
The registered reason “cancer” is therefore not very precise. In addition, the
reporting of diagnoses might vary over time, and by certifying physicians.
Depression is an example of a diagnosis that was commonly reported as a
secondary cause for disability pension receipt in women with breast cancer. We
cannot rule out that the proportion of women and men with cancer who were
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absent from work due of mental disorders was underestimated, since such
conditions were considered to be cancer-related and thus coded as cancer. This
might attenuate the role of mental disorders in the risk of absence from work in
cancer patients (i.e., the observed hazard ratio is closer to 1 than the causal hazard
ratio). Similar reasoning applies to the other non-cancer causes.
An additional issue was that only the first diagnosis for the period of sick leave or
disability pension receipt is recorded in MiDAS; any changes in diagnosis are not
recorded. Based on a report by the Swedish Social Insurance Inspectorate, around
7% of all sick-leave diagnoses are later changed to a diagnosis within another
diagnostic group [151]. This percentage is lower for diagnoses related to mental
disorders (F00–F99), and higher for diagnoses related to signs and symptoms of
disease (R00–R99).
6.2.3 Confounding
A potential limitation of the studies included in this thesis is residual confounding.
For example, we lacked information on factors related to work load and work
environment, which are important risk factors for sick leave and disability pension
receipt. Other than the most severe medical conditions captured by the Patient
Register, we also lacked information on general health status, another important
risk factor. We further had little to no data on some prognosis and treatment-related
factors, such as dose and duration of treatment. In our analysis, however, we were
able to control for many other possible confounders, of which age at diagnosis,
time since diagnosis, previous sick leave, and tumor stage were the most important.
In Study I, confounding was a concern, and analyses were adjusted for nearly
all clinical and sociodemographic variables on which we had information.
However, the relative risk estimates did not change substantially by, for example,
adding income and type of occupation to a model that already included education.
Furthermore, any unmeasured confounder would need to be strongly associated
with the outcome to completely explain away the association between surgery
type and return to work. However, it is still possible that the association could be
explained by a priori beliefs of faster recovery after robot-assisted surgery, which
might have influenced how the doctors prescribed sick leave. Likewise, men who
needed to go back to work earlier may have actively chosen robot-assisted surgery.
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A priori beliefs are less of an issue in the analysis of our second outcome, days
lost from work after return to work.
In Study II, confounding by indication was the main concern: having a more
aggressive tumor is both an indication for undergoing radical treatment and a risk
factor for cancer progression, which in itself increased the risk of sick leave and
disability pension receipt. To reduce confounding by indication, the analysis was
stratified by risk category. To examine the influence of other possible confounders,
we stratified the analysis by age at diagnosis, level of education, and prior sick
leave. The pattern of prostate cancer-specific sick leave remained the same: men
on active surveillance had less than half as many days on sick leave as men who
underwent primary radical therapy within all subgroups.
In Studies III and IV, confounding by calendar period was a concern due to
the long study period. Both the treatment of breast cancer and the likelihood
of receiving disability benefits changed during the period under study. Calendar
period was therefore either included as a covariate in the models, or accounted
for by applying a period approach [152], which better reflects the experiences of
women diagnosed in more recent years. In analyses comparing women with breast
cancer to breast cancer-free women, unadjusted estimates (not controlling for any
other factor than the matching factors and time since diagnosis) were in general
similar to adjusted estimates.
6.2.4 Random variability
The impact of random error due to sampling variability was minimized by the use
of large cohorts of women and men. However, some of our analyses were based
on a small number of events, especially the cause-specific analyses in Study IV,
which increases the risk of observing an association as a result of random error
(i.e. chance finding).
6.3 Comparison with previous research
6.3.1 Studies on prostate cancer
At least three previous studies have compared time to return to work after
robot-assisted or retropubic radical prostatectomy [60, 62, 64], two of which were
published after our study had been performed (Table 6.1). The median time for
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return to work after open surgery in our study was 48 days, which was similar to
the previous studies. Time to return to work after robot-assisted surgery varied
considerably more, from 26 to 42 days. Given the randomized design, the study
by Yaxley et al. best reflects the impact of robot-assisted surgery on return to
work, although some criticism has been directed at the 2-surgeon design of this
trial [153]. Randomization overcomes the issue of confounding, which was a
major limitation in both our study and the study by Hohwü et al. As in a previous
study on Norwegian men [74], we found that the surgical technique did not have a
long-term influence on work.
Table 6.1: Time to return to work after robot-assisted (RARP) and retropubic radical
prostatectomy (RRP)
Author Study Design n Median, days
RARP RRP
Hohwü [60] Cohort 274 26 55
Plym (Study I) Cohort 2,571 35 48
Yaxley [64] Randomized controlled 129 43 47
von Mechow [62] Cohort 1,451 42 42
Only a handful of studies have examined the impact of other types of treatment
for prostate cancer on absence from work [59, 66, 76]. The findings of our study
are largely in agreement with those studies, although previous studies are restricted
to the first 2 years after diagnosis. In the Danish study by Sveistrup et al., 91%
of men treated with radiotherapy (in all risk categories) were free from sick leave,
disability pension receipt and death 1 year after diagnosis [66]. This estimate
is very close to our estimate of 94% at the same point in time, although our
analysis was restricted to men with low- or intermediate-risk cancer. Bradley et
al. examined the mean number of days lost from work in the first 6 months after
diagnosis (all stages of prostate cancer were included) [59]. Similar to our study,
men treated with surgery or radiotherapy lost more days from work (33 and 10
days, respectively) than men with no treatment, who on average lost 3 days. In both
our study and others, direct comparisons of treatments are generally complicated,
since cancer characteristics are more adverse in men receiving primary radical
therapy compared with men on active surveillance.
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Our study is the first to report that men who remained on active surveillance had
nearly no sick leave related to prostate cancer; the majority of days recorded were
accounted for by men with subsequent radical therapy. Our study is also the first
to report on sick leave due to mental disorders such as depression, anxiety, and
stress-related conditions. During the first 5 years after diagnosis, men on active
surveillance had close to the same number of days on sick leave due to mental
disorders as prostate cancer-free men (6 days). The number of days was slightly
higher after primary radical prostatectomy (8 days) and after radiotherapy (12
days). Our results are in agreement with conclusions drawn from a systematic
review in which active surveillance was generally not associated with reduced
psychological well-being [154]. However, some criticism has been directed at
the methodology used in previous studies, especially regarding the the lack of an
appropriate control group [155].
6.3.2 Studies on breast cancer
In comparison with that for prostate cancer, the number of previous studies on
sick leave and work in women with breast cancer is considerably larger. However,
no previous study has presented estimates on work-life expectancy that combine
different work-related outcomes and summarize the impact on work until
retirement. Most earlier studies have included only 1 or 2 work-related outcomes
and presented measures of effect at a specific point in time. A few studies report
on time lost from work within a specific year [86, 89, 90]. Estimates of the
amount of time lost due to death (loss in life expectancy) have been presented
previously: women with breast cancer aged 50 years at diagnosis lost on average 7
years of life in comparison with population controls in an Australian study [156].
We also estimated how certain treatments influenced the loss of working time. In
agreement with previous studies on the risk of receiving disability pension [92, 94],
we observed that axillary lymph node dissection increased the amount of time lost
from work. However, we found no evidence that mastectomy increased the loss
of working time, which is in agreement with some [94, 100], but not all previous
studies [92]. Chemotherapy was also not associated with an increased loss of
working time, a finding that requires further consideration given that chemotherapy
has been associated with an increased risk of disability pension receipt and other
work-related outcomes in several previous studies [92, 94, 100]. In contrast to
the other studies, our outcome is a combination of disability pension receipt, old-
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age retirement, and death. Our findings might reflect that the survival benefit
of receiving chemotherapy outweighs the increased risk of receiving disability
benefits. Furthermore, our estimates should be viewed as restrictive estimates of
the permanent loss of working time after a breast cancer diagnosis, since sick leave
or part-time disability pension of less than 75% are not included.
Comparison with previous research is also complicated by country-specific
settings. In studies performed in Northern European countries, chemotherapy has
been associated with sick leave and disability pension receipt [92, 94], but not
with unemployment [94, 101]. In contrast, chemotherapy was associated with
unemployment in a US-based study [100]. Rather than contradicting each other,
these contrasting findings may reflect differences in insurance systems and the
protection of employees.
In agreement with previous research [95, 96, 98, 104–108], we found that
fatigue-related conditions and lymphedema were underlying causes of absence
from work in some women with breast cancer. We also observed that women with
breast cancer had a higher risk of sick leave and disability pension receipt due to
mental disorders compared with breast cancer-free women. This appears to
contradict a conclusion in the study by Kvillemo et al., in which the authors stated
that “the higher prevalence of sickness absence and disability pension was a result
of breast cancer only, not because of mental or other somatic diagnoses” [86, p. 6].
This conclusion only relates to the absolute effect of breast cancer on disability
pension due to mental disorders. In absolute terms, differences for causes other
than cancer were small also in our study, reflecting the fact that it is relatively rare
to be on disability pension due to, for example, depression. In addition, women
with breast cancer have strong competing events, such as death and disability
pension receipt due to cancer.
Women with breast cancer were also at increased risk of disability pension
receipt due to cardiovascular and inflammatory diseases. Although this has not
been studied previously, our findings are not unexpected considering that previous
studies have found evidence of increased risks of both cardiovascular [157–159]
and some types of inflammatory diseases [160, 161] after diagnosis and treatment
for breast cancer. However, our study was not designed to study the underlying
mechanism behind the association, which might be related to the treatment for
breast cancer, but also to shared risk factors.
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No previous studies are available for comparison on the impact of treatment
on cause-specific disability pension receipt. Except for endocrine therapy, all of
the treatment modalities studied increased the risk of disability pension receipt
due to cancer. Mastectomy was the only factor that was significantly associated
with an increased risk of disability pension receipt due to mental disorders. It has
previously been suggested that mastectomy increases the risk of psychological
distress in young women [162], although we cannot rule out residual confounding
as an explanation. Axillary lymph node dissection was the only factor significantly
associated with disability pension receipt due to musculoskeletal disorders, most
likely reflecting morbidity related to arm and shoulder functioning.
6.4 Generalizability
Due to the population-based and partly nationwide study designs, most of our
results can be generalized to working-aged women and men diagnosed with breast
or prostate cancer in Sweden. However, the presented probabilities of sick leave
and disability pension receipt are specific to the calendar period under study, and
are expected to change if the treatment for cancer changes or if the legislation for
social insurance undergoes major changes. For example, the rules for obtaining
disability pension are much stricter now than in the early 2000s, and disability
pension receipt has become less common.
Parts of our results can also be generalized to women and men in other countries
with high labor force participation. It is reasonable to assume that the adverse
event profile after treatment for breast or prostate cancer does not differ across
countries, and the relative impact of a specific treatment strategy on working life
is likely to be similar. An assuring example are the results in Study I, which had
remarkably similar estimates of time to return to work after radical retropubic
prostatectomy as studies performed in Germany and Australia [62, 64].
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7 Conclusions and implications
As a whole, the results of the present thesis show that diagnosis and treatment of
breast and prostate cancer have a considerable impact on sick leave and work, in
particular during the first year following diagnosis. The only exception to this was
men with prostate cancer remaining on active surveillance, who spent a similar
amount of time on sick leave in the first 5 years after diagnosis as prostate cancer-
free men. At year 5, the type of initial treatment strategy for prostate cancer
had little or no influence on sick leave and disability pension receipt. With the
exception of women with in situ breast cancer and subgroups of women with early-
stage breast cancer, breast cancer had a considerable impact on amount of time lost
from work until retirement. In addition to cancer progression, both psychological
and physical morbidity secondary to breast cancer diagnosis and treatment were
underlying causes of absence from work.
The implications of the results in this thesis are at least 5-fold: First, our results
highlight that continuous follow-up and monitoring of adverse events following
treatment for cancer is needed to reduce the impact on daily activities such as work.
We have identified several medical reasons for absence from work, and intervening
and mitigating some of these at an early stage may be possible.
Second, our findings can be used to improve and tailor vocational rehabilitation
programs. Reintegration into work is an important aspect of quality of life, and
whenever possible efforts should be made to facilitate this process. In this thesis,
we have identified not only individuals at risk for leaving the labor market, but also
studied the underlying reasons. This information is particularly useful because it
helps identify the areas of expertise and content needed for rehabilitation programs.
It also provides helpful information for employers by increasing the understanding
of what type of work-place adaptations may be expected to be necessary.
Third, our findings can be used as additional guidance for treatment decisions
for localized prostate cancer, which can be difficult because they involve a balance
between potential harm and benefits. Although the type of treatment strategy had
an influence on sick leave and work, our findings showed that the long-term impact
on work was similar across treatment strategies. However, the studies included in
this thesis were not randomized, and the findings must be viewed in conjunction
with results from other studies.
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Fourth, the absolute measures presented in this study are easy to understand for
lay men, and can be used by the treating physician when communicating with
patients about the possible implications of treatment on working life. Raising
awareness of potential future health problems can help in mitigating the
consequences on daily activities.
Fifth, our results are not only important for setting clinical guidelines, but also
for developing cancer-specific policies for sick leave. Such policies should include
procedures taking not only physical but also psychological consequences of a
cancer diagnosis into account.
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8 Future perspectives
With the number of women and men living with a history of breast, prostate, or
other cancer expected to increase, issues related to sick leave and work will gain
importance. Reintegration into work is not only important for the individual
diagnosed with cancer, but also for employers and the society as a whole.
Productivity losses due to sick leave and disability pension have been estimated to
account for over 30% of the total cost of breast cancer in Sweden [163].
Future studies can provide results to improve reintegration into work in several
ways. It is essential to improve our understanding of the underlying causes of
absence from work in cancer patients, for example, by extracting more detailed
information on reasons for sick leave from medical charts, or by surveying
patients. Such investigations can also be used to validate the information available
in MiDAS, which has not been done to date. To separate out the effects of cancer
progression and the effects of adverse events resulting from treatment, future
studies should, if possible, include information on local relapse. Furthermore,
separately examining the underlying reasons for part and full-time sick leave and
disability pension receipt is also likely to reveal new insights.
To better understand the effects of a specific treatment, detailed information not
only on the treatment type, but also on the dosage and duration of treatment is
needed. This information is partly available in the Cancer Quality Registers for
women and men diagnosed in more recent years. Also, the ongoing development
of real-time databases with prospective registration of oncological drugs,
including information on reasons for discontinuation and side effects, will open
up new possibilities. Due to the observational nature of such studies, methods
from the field of causal inference would preferably be applied [164]. However, a
randomized study represents the optimal design, and the importance of including
work-related outcomes also in randomized trials has been recognized [64, 78].
It would also be of value to study what type of rehabilitation women and men
diagnosed with breast or prostate cancer need in order to remain in the work force,
ideally by performing a study examining the effect of an intervention on sick
leave and work. It has recently been suggested that flexible sick leave (i.e., the
patient decides on which days she or he feels well enough to work) can reduce
the number of days on sick leave after a cancer diagnosis, with positive effects on
psychological wellbeing [165].
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